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vWHAT IS A WITNESS SEMINAR?
The Witness Seminar is a specialized form of oral history, where several 
individuals associated with a particular set of circumstances or events are invited 
to meet together to discuss, debate, and agree or disagree about their memories. 
The meeting is recorded, transcribed, and edited for publication. 
This format was first devised and used by the Wellcome Trust’s History of 
Twentieth Century Medicine Group in 1993 to address issues associated with 
the discovery of monoclonal antibodies. We developed this approach after 
holding a conventional seminar, given by a medical historian, on the discovery 
of interferon. Many members of the invited audience were scientists or others 
involved in that work, and the detailed and revealing discussion session 
afterwards alerted us to the importance of recording ‘communal’ eyewitness 
testimonies. We learned that the Institute for Contemporary British History 
held meetings to examine modern political, diplomatic, and economic history, 
which they called Witness Seminars, and this seemed a suitable title for us to 
use also. 
The unexpected success of our first Witness Seminar, as assessed by the 
willingness of the participants to attend, speak frankly, agree and disagree, and 
also by many requests for its transcript, encouraged us to develop the Witness 
Seminar model into a full programme, and since then more than 60 meetings 
have been held and published on a wide array of biomedical topics.1 These 
seminars have proved an ideal way to bring together clinicians, scientists, and 
others interested in contemporary medical history to share their memories. We 
are not seeking a consensus, but are providing the opportunity to hear an array 
of voices, many little known, of individuals who were ‘there at the time’ and 
thus able to question, ratify, or disagree with others’ accounts – a form of open 
peer-review. The material records of the meeting also create archival sources for 
present and future use.
The History of Twentieth Century Medicine Group became a part of the 
Wellcome Trust’s Centre for the History of Medicine at UCL in October 
2000 and remained so until September 2010. It has been part of the School 
of History, Queen Mary University of London, since October 2010, as the 
History of Modern Biomedicine Research Group, which the Wellcome Trust 
1  See pages 113–19 for a full list of Witness Seminars held, details of the published volumes, and other 
related publications.
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funds principally under a Strategic Award entitled ‘The Makers of Modern 
Biomedicine’. The Witness Seminar format continues to be a major part of that 
programme, although now the subjects are largely focused on areas of strategic 
importance to the Wellcome Trust, including the neurosciences, clinical 
genetics, and medical technology.2
Once an appropriate topic has been agreed, usually after discussion with 
a specialist adviser, suitable participants are identified and invited. As the 
organization of the seminar progresses and the participants’ list is compiled, a 
flexible outline plan for the meeting is devised, with assistance from the meeting’s 
designated chairman/moderator. Each participant is sent an attendance list and 
a copy of this programme before the meeting.  Seminars last for about four 
hours; occasionally full-day meetings have been held. After each meeting the 
raw transcript is sent to every participant, each of whom is asked to check his or 
her own contribution and to provide brief biographical details for an appendix. 
The editors incorporate participants’ minor corrections and turn the transcript 
into readable text, with footnotes, appendices, a glossary, and a bibliography. 
Extensive research and liaison with the participants is conducted to produce 
the final script, which is then sent to every contributor for approval and to 
assign copyright to the Wellcome Trust. Copies of the original, and edited, 
transcripts and additional correspondence generated by the editorial process are 
all deposited with the records of each meeting in the Wellcome Library, London 
(archival reference GC/253) and are available for study.
For all our volumes, we hope that, even if the precise details of the more 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable to all readers. Our aim is that the volumes 
inform those with a general interest in the history of modern medicine and 
medical science; provide historians with new insights, fresh material for study, 
and further themes for research; and emphasize to the participants that their 
own working lives are of proper and necessary concern to historians.
2  See our Group’s website at www.histmodbiomed.org. 
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INTRODUCTION
It is my pleasure to introduce the latest Witness Seminar volume from the History 
of Modern Biomedicine Research Group at Queen Mary University of London. 
The topic is one close to my heart, as my first edited book was on the topic of 
ethics in clinical genetics: Case Analysis in Clinical Ethics was a collaboration 
with the chair of the present seminar, Professor Anneke Lucassen, and with one 
of the participants, Professor Michael Parker, as well as a distinguished Dutch 
colleague, Professor Guy Widdershoven.1 
In the late 1990s and early 2000s clinical genetics was one of the central topics 
of the then fast developing and professionalizing field of academic bioethics. A 
number of different factors made clinical ethics exemplary of what contemporary 
bioethics was trying to do. One key element was the role of research funders. In 
the UK, for example, the Wellcome Trust decided to broaden its own funding 
portfolio in ‘medicine, society and history’ to include biomedical ethics, with a 
quite explicit agenda to develop not only ‘public understanding’ of the medical 
sciences but also primary research into ethical issues. Such research was to be 
interdisciplinary in method, with a strong focus on policy relevance for society 
at large but also for the Trust intramurally. The research funded by the Trust was 
not only to provide specific answers to specific policy questions but also to be a 
mechanism for capacity building for UK bioethics itself. Many people now active 
in bioethics in the UK were either trained through funding from the Wellcome 
Trust for PhDs and research fellowships or clinician training fellowships. Others 
who entered bioethics later in their careers (including myself ) obtained their 
first research project grants from the Trust. And still others, who may have been 
active in teaching medical ethics, began to reshape their research and publication 
activities in order to take advantage of Wellcome funding. 
Much of this activity was driven by the ordinary internal processes of discipline 
formation, but equally there were push factors. As is discussed in the seminar, the 
General Medical Council began to require medical ethics to be formally taught 
as part of undergraduate medical education in the early 1990s. But the drive, 
under the pressure of the Research Assessment Exercises and increasingly stringent 
university funding conditions, for medical schools to become highly research 
intensive and to underwrite their high operating costs with increased external 
research funding led to significant pressure on those employed to teach medical 
ethics in medical schools to do externally funded research. As none of the Research 
1  Ashcroft et al. (eds) (2005). 
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Councils took medical ethics or bioethics to be ‘core business’ of their funding 
streams, the position of the Wellcome Trust was unique, and its influence over the 
type, form, and topic of research funding of bioethics research was critical.
Although, initially, the Trust was very open about the kinds of topics it was 
prepared to fund, provided these were practically relevant and assisted in 
capacity building, at a relatively early stage it decided to prioritize three areas: 
international research ethics (which was a special area of interest for the Trust 
given its overseas research centres), neurosciences and ethics, and genetics.2 
Most of the work eventually funded by the Trust in the first ten years or so 
of its biomedical ethics funding was in the area of genetics, specifically genetic 
research.  So, one way to characterize biomedical ethics and its interest in genetics 
in the late 1990s and early 2000s is to see it as interdisciplinary research into the 
ethical issues arising from research in genetics, in order to produce evidence for 
policy. Understood this way, bioethics begins to become quite different from 
medical ethics as it had been practised in UK universities and medical schools 
from the late 1960s onwards. Up to that point, medical ethics could be described 
as fundamentally a pedagogical and pastoral discipline, concerned with ‘moral 
dilemmas’, and very much focused on the practical decision-making of clinicians 
and medical students. However, we also need to notice a third strand in the 
reshaping of bioethics, equally important in some ways to the other two, but less 
frequently acknowledged.  One reason the Wellcome Trust wanted to emphasize 
both interdisciplinarity and research was a perception that hitherto most public 
discussion of bioethical topics – for example, the Warnock Committee on Human 
Fertilisation and the Embryo (1984) – focused primarily on discussion within 
small groups of the ‘great and the good’, and armchair reflection on concepts and 
intuitions (what is pejoratively referred to as ‘Oxford philosophy’).3 
On the one hand these methods were not congenial to the Trust, inasmuch as its 
main efforts were devoted to research in the sciences and to the role of empirical 
evidence; then, as now, research funders struggle to understand exactly what it 
is that philosophers do, and why, and how to tell whether it is any good. On 
the other hand, there was a persistent unease that the sort of ethical arguments 
2  The Review of the Wellcome Trust Policy Unit (c.2001) states ‘The Biomedical Ethics Programme 
was set up as a fixed-term, five-year initiative at the Wellcome Trust in 1997, with a budget of £5 million. 
The broad aim of the Programme is to support empirical research into the ethical, legal, social, and public 
policy aspects of developments in biomedical science, with a focus on two areas: neuroscience (including 
mental health) and genetics.’ It also notes that the scope of the programme should be widened to include 
international research; see pages 4 and 12.
3  Committee of Inquiry into Human Fertilisation and Embryology and Warnock (1984).  
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produced by elite groups might systematically fail to grasp what was of concern to 
the public at large, or to important sections thereof. This is just a concrete instance 
of the trend away from the ‘public understanding of science’ model developed by 
the Royal Society at the beginning of the 1990s to the broader and more dialogical 
conception of ‘public engagement with science’. It began to be felt quite widely 
within the scientific establishment that for the governance of science to be legitimate 
(that is, not only normatively acceptable but actually accepted) the public had to 
be engaged in genuine two-way dialogue.  It is, as they say, no accident that in the 
earliest days of the biomedical ethics funding stream it was led by a leading science 
journalist (Tom Wilkie) and a sociologist-activist (Patricia Spallone) who saw 
biomedical ethics as a way of expanding this kind of engagement. Although this 
might seem an unusual stance for a major research charity to take, and although 
the Wellcome Trust’s approach to public engagement and biomedical ethics were 
to change quite rapidly and significantly through the 2000s, and after, this position 
is explicable if we notice that much of the discussion of ethics and genetics outside 
the higher education sector was led by activist groups such as Genewatch UK, 
which though small were very effectively networked in the media. The stances 
of these groups tend to be shaped by the positions of the 1970s radical science 
movement, and were in general highly sceptical about the benefits to humankind, 
which might accrue from genetic science and technologies.4 Although nothing 
in human genetics provoked the kind of large-scale and polarized reactions that 
genetically modified foods did throughout the 2000s, many policy makers and 
scientists worried that such a reaction might arise. It is this concern, if not with 
democracy as such, then at least with ‘societal risk management’, which motivated 
a lot of activity in bioethics research funding.
Reading over the transcript of the seminar, several of the themes I have described 
above do emerge, but it is interesting to me how different the geneticists’ 
and clinicians’ construal of what was going on was to mine, as it developed 
over the past 20 or so years.  For one thing, unsurprisingly, the clinicians are 
powerfully engaged by questions of what it is to practise medicine well, how 
to care for patients when there is little or nothing that can be done to change 
their condition (as was the case throughout much of the period under review), 
and how it is this question of ‘good medicine’ that is central, rather than, say, 
ethical principle or sociological evidence about what patients and their families 
wanted, or indeed wider societal issues. Inasmuch as wider societal issues did 
arise, these were framed very much in terms of moving the conversation away 
from genetics-as-eugenics to genetics-as-family-medicine or, especially, genetics-
4  For an overview of the UK’s radical science movement, see Bell (2015). 
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as-counselling. The conception of counselling itself mutates rapidly away from 
advice-giving towards something more psychotherapeutic in the form of ‘non-
directive counselling’ and helping patients to make their own best decisions. In 
turn this is seen as being in tension with both what good medicine requires and 
with what patients actually want from professionals. The question of eugenics 
seems largely to disappear as not arising in, or salient to, what actually happens 
in clinic. Instead, two other kinds of difficulty do become central.
One has to do with research. A clinician has care of her patients, and the difficulty 
of working out how to help patients who no longer come one-by-one, but instead 
in family groups, with all the troubles that attend all families (except, perhaps, 
Tolstoy’s mythical happy ones – all of which are alike in that they have the common 
property of non-existence). In addition, for most clinical geneticists, much of the 
time, the disorders they are called upon to diagnose may be rare, or even previously 
unknown, such that every patient is actually or potentially a research subject, not 
only because they are ‘interesting material’ but in order to do anything for them 
at all, clinically. The need for cooperation between clinicians, and indeed, often, 
between families, and also internationally, creates both a research network and a 
clinical network, with quite different styles of governance and legal and regulatory 
rules being brought into contact.   Consequently, confusion and delay often arises, 
and out of this mess emerges a call for principles, or advice, where the bioethics 
community is purportedly expert, even where it is divided and regularly required to 
make things up as it goes along. (A very good example of this is the tangled web of 
ethical discussion relating to human tissue before and after the Alder Hey scandal in 
the early 2000s – compare and contrast the Nuffield Council on Bioethics’ reports 
on human tissue in 1995 and 2011 and the Human Tissue Act in England of 2004).5 
As we move into the era of the mainstreaming of genomics, the previous regime 
of clinical genetics focusing on careful and painstaking work to solve puzzles 
in small numbers of patients known intimately to their clinicians seems wildly 
different to the world of big data analytics, statistical inference, electronic patient 
records, and whole genome scanning. This in turn is in a complex and as yet 
unresolved relationship with the model of genetic governance arising out of genetic 
epidemiology (for example, the work of ALSPAC/‘Children of the Nineties’).6  We 
5  Nuffield Council on Bioethics (1995, 2011), and the Human Tissue Act 2004 (c.30). 
6  My first project as Principal Investigator was a Wellcome Trust-funded study on ‘ethical perspectives on 
epidemiological genetics: participants’ perspectives’, involving focus groups and interviews with children and 
parents involved in the Avon Longitudinal Study of Pregnancy and Childhood (ALSPAC) (1997–2000). For 
ALSPAC, see also Overy, Reynolds, and Tansey (eds) (2012). 
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see here both the classic sociological transition from a social organization based on 
trust and status to one based on rule and contract; and now from one based on rule 
and contract to one based on… what? Algorithm and code? Time will tell.
The other kind of difficulty is emotional. Several of the participants at the seminar 
referred to the emotional labour, indeed the emotional burden, of their work. 
To some extent we can understand the emergent role of the genetic counsellor 
as an institutional solution to this problem, but although this might transform 
the location, and some of the modalities, of that emotional labour, it does not 
displace it entirely. Yet almost no work was done within bioethics on the affective 
dimension of clinical work and its role in thinking ethically about such work. 
This is consistent with what happened in medical education in the period, with 
a transition from a training in professionalism that followed an apprenticeship 
model – long after this had been abandoned in the medical sciences – to a 
formalized model requiring training in ‘communication skills’ alongside, and 
separated from ‘medical ethics and law’. Yet even communication skills training, 
in figuring the clinical relationship as something reducible to a learnable set of 
skills, framed by an externally imposed set of ethical and legal regulations, ignored 
or possibly tried to overcome, the affective relationship central to medical care.
In conclusion: in addition to the invaluable historical testimony shared in this 
seminar, we have an invaluable resource for thinking about what bioethics is for, 
what good medicine is, and various ways in which regulation and principle displace 
and transform but do not replace or overcome professionalism, care, emotion, 
and indeed the embodied selves of both patients and clinicians. Clinical genetics 
in this sense represents the exemplary medical specialty: doing ethics while doing 
medicine, in the face of emotional frailty and scientific doubt. Just not, I think, in 
the way the Wellcome Trust – and bioethicists – thought it was back in the 1990s.
Professor Richard Ashcroft
Queen Mary University of London
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Professor Tilli Tansey:  Let me introduce myself: I’m Tilli Tansey and I’m 
Professor of the History of Modern Medical Sciences at Queen Mary University 
of London, and the convenor of these Witness Seminars, which are opportunities 
to get behind the written record of modern history, of modern science and 
medicine, to find out what really happened. Who were the drivers; what did 
happen; why did it happen? Things were never inevitable; there were usually 
reasons why things happened or why they didn’t happen, so those are the 
stories we hope that you will tell us about this afternoon, how they developed 
in relation to the development of ethics and a clear code of practice in research 
and clinical genetics. 
We hope today to get behind the published records, the official records, and 
the published literature, and, with the advice of Peter Harper, we’ve devised 
an outline programme of themes to try to address.1 This is, however, not 
a rigid programme. If at any point there are things that are not included 
that you wish to say, do please say them. This is your opportunity to tell 
your history. 
The founding medical geneticists and ethical issues
Early genetic counselling: The emergence of ‘non-directiveness’ as a core principle
Recognition of special ethical problems in clinical genetics practice and research: what are 
they and how unique to genetics?
• Reproductive issues
• Presymptomatic genetic testing
• Confidentiality and consent issues; genetic testing of children
• Population screening
Involvement of social scientists and the humanities in genetics
Development of genetic counsellors and their influence on ethical aspects of practice
Formal bodies involved in ethics and genetics: Nuffield Council on Bioethics, Human 
Genetics Commission, etc. 
Table 1: Witness Seminar outline programme2
1  Professor Peter Harper is a consultant to the History of Modern Biomedicine Research Group on clinical 
genetics for the ‘Makers of Modern Biomedicine: Testimonies and Legacy’ project, funded by a Wellcome 
Trust Strategic Award. 
2  The outline programme was circulated to participants in advance of the Witness Seminar.
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An important part of any of these meetings is, of course, finding a suitable 
chairman, and that really is a misnomer because this is not a meeting in which 
we want some sort of consensus to emerge but really we want to hear the diversity 
of views, opinions, and experiences. I think it’s probably better to use the word 
facilitator, and we’re delighted that Anneke Lucassen has agreed to adopt that 
role for us. Basically, she’s going to keep you all in order and get us to tea and 
drinks afterwards on time, so thank you very much, Anneke, and over to you.
Professor Anneke Lucassen:  Thank you very much. I think I know most of 
you. I’m an academic clinician in Southampton and I’ve had a longstanding 
interest in exploring the ethical issues raised in clinical genetics. And one of the 
ways I’ve developed that interest in practice is, over the last 10 years, through 
a group with Mike Parker, Angus Clarke, who are here today, and Tara Clancy, 
called the Genethics Club.3 Apparently ‘club’ is a bit exclusive, so we call it the 
Genethics Forum now – this is a meeting for anyone interested to come and talk 
about practical issues that raise ethical aspects in genetics.
We started off that meeting as a one-off in 2001, thinking that we’d sort out all 
the ethical issues in one or two meetings, but actually it grew from there and 
3  The Genethics Club (later Forum) was founded in 2001; see Lucassen and Parker (2006), and also 
on the Ethox Centre’s website; www.ndph.ox.ac.uk/research/ethox-centre/ethics-support/genethics-club 
(accessed 28 July 2015). See also note 152. Dr Tara Clancy is a Consultant Genetic Counsellor and Lecturer 
in Medical Genetics at the Manchester Centre for Genomic Medicine, Central Manchester University 
Hospitals NHS Foundation Trust; http://mangen.co.uk/about-us/OurStaff/Consultants/TaraClancy.php 
(accessed 3 July 2015).
Figure 1: Professor Tilli Tansey, Professor Anneke Lucassen
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there’s been a continued demand to keep them going, and we’ve got our 40th 
meeting next year. I hope to draw on some of that experience. 
Today, I’m not going to be chairing, I’m going to be facilitating as you discuss 
things as they come up, so what I wanted to do was ask Peter Harper to start 
the ball rolling and then hope that you’ll all contribute. I might ask some of 
you directly to contribute bits and pieces, but please also volunteer if you’ve got 
something to say and hopefully with a nice, free-floating structure like that we’ll 
get some good discussion going. Right, I should just say that I’m a newbie to 
these seminars, and a lot of you, I know, have been before so you’ll have to direct 
me if I’m not doing it quite right. Peter, over to you.
Professor Peter Harper:  Anneke and Tilli asked would I start things going by 
exploring the question: how did ethics and ethical issues, how did they first get 
into what we might loosely call medical genetics? I think it’s useful to do this 
because some, indeed most, of the founding people in the field, both in this 
country and in other countries are no longer living and probably quite a few of 
you won’t have ever known them. I’ve been lucky in the sense that I’m old enough 
to have known quite a few of them and so are some other people here. I think one 
has to start from the perspective that up until the end of World War II the whole 
area of human genetics was in very bad standing following the abuses of eugenics, 
which had really gone on for the first half of the twentieth century.4 This had, in 
4  See, for example, Harper (2008), chapter 15, ‘Eugenics’, pages 405–27. 
Figure 2: Professor Peter Harper
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fact, alienated a lot of people, a lot of scientists, from taking part in the field. Yet 
my feeling, which people can argue with, is that since that time, over the past 50 
years, ethics has become very strongly embedded in the ethos and the practice of 
medical genetics, perhaps particularly clinical genetics. The question is: how did 
it get like that? It might perhaps have gone the other way. 
So, thinking of where to start, actually a good person to start with, though I did 
not know him well, and there are people here who can say much more, is Lionel 
Penrose at London’s Galton Laboratory. After he came back from Canada, I 
think it was in 1945, and took the Galton Chair, which was originally called 
the Chair of Eugenics, but he managed to get that and his department’s name 
changed, he really set the standard for something quite new. 5 He, I think it’s 
fair to say, confronted the previous situation pretty well head-on, and you can 
see that in the inaugural lecture that he gave, in which he used phenylketonuria 
as an example.6 But I think it was a lot wider than that, and one of the things 
that I’ve been very impressed with while interviewing early people in the field 
around the world, doing recorded interviews, is, first of all, actually, the number 
of people who got their initial training with him.7 Not just people in this country 
but people from continental European countries – for instance, people like Jean 
Frézal in France, Jan Mohr in Copenhagen, and a number from North America 
like Arno Motulsky and Barton Childs.8 I’ve been very impressed, not just by 
5  Professor Lionel Sharples Penrose (1898–1972) was Galton Professor of Human Genetics from 1945 
to 1965 at University College London (UCL); for further biographical details see Harris (1973). For the 
Galton Laboratory’s history at UCL, see Jones (1993), and also Harper (2008), pages 235–40.
6  Penrose (1946).
7  Transcripts of Professor Peter Harper’s interviews with leading medical geneticists for the Genetics 
and Medicine Historical Network, based at Cardiff University, are freely available to download at 
https://genmedhist.eshg.org/39.0.html (accessed 11 January 2016). 
8  Dr Jean Frézal (1922–2007) was a geneticist based at the Hôpital Necker, Paris, where he developed 
medical genetics research and clinical services. Jan Mohr (1921–2009) was the Head of the Institute of Medical 
Genetics at the University of Oslo, then Professor of Human Genetics at Copenhagen University from 1964 
to 1991; see http://icmm.ku.dk/klinikken/the_clinic/history/jan_mohr/ (accessed 7 July 2015). See Professor 
Peter Harper’s interviews with Frézal and Mohr for the Genetics and Medicine Historical Network at 
https://genmedhist.eshg.org/39.0.html (accessed 11 January 2016). Dr Arno Motulsky developed medical 
genetics at the University of Washington, where he is now Professor Emeritus of Medicine and Genome Sciences; 
see further biographical details at http://depts.washington.edu/medgen/faculty/Arno_Motulsky.shtml (accessed 
7 July 2015). Professor Barton Childs MD (d. 2010) was the first Director of Genetics in the Department of Pediatrics 
at Johns Hopkins University, Baltimore; see an obituary at www.hopkinschildrens.org/barton-childs-obituary.aspx. 
(accessed 7 July 2015). 
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the number of key people who were very much influenced by training with him 
but by the tremendous respect in which they held him. I think, actually, this 
goes directly to this word ‘respect’ because it’s fair to say Penrose had a great deal 
of respect for the subjects he was working with who, for the most part, were 
people who were mentally handicapped. That’s a striking contrast to what had 
happened before the war, in many cases, where really there was no respect for 
subjects, and these individuals were often classed as subhuman or just viewed as 
problems. So there was that and, of course, he had great respect for the facts too 
in terms of the rigorous science. 
All the people I’ve interviewed who have worked with him, unhesitatingly, have 
named him when I’ve asked who has been the greatest influence. Just about 
all of them have given his name if they have worked with him, so I think he 
had a huge influence, but, on the other hand, I don’t feel that Lionel Penrose 
was himself a clinical geneticist. He was clinical, very much so, and he was 
a geneticist, but clinical genetics hadn’t really taken shape at that point and 
it wouldn’t until the next generation. So his role was to set the ethos, as you 
might say, and to mould the people who would themselves be the first practising 
clinical geneticists. When we think about it now, who were those people? 
I think clinical medical genetics really first got off the ground in an organized 
way not in Britain but in North America, and there are three key people I’d 
like just to mention who I think paved the way for it there: these are Clarke 
Fraser in Montreal, who started a unit there about 1950; Arno Motulsky in 
Seattle; and, of course, Victor McKusick in Baltimore, both of whom founded 
departments or divisions of departments in 1957.9 They, in turn, trained large 
numbers of people, and I think it’s this fact more than their actual research that 
stands out and has made them iconic figures throughout the world; not just 
North America because perhaps especially Victor McKusick was responsible 
for training people in clinical genetics from, really, everywhere, including 
a considerable number from this country.10 Then the people who had been 
trained by McKusick, Fraser, and Motulsky went on to train many other 
people themselves and formed really a considerable body of people in the early 
years of medical genetics. 
9 Dr (Frank) Clarke Fraser (1920–2014) founded the Human Genetics Unit at the Montreal Children’s 
Hospital in 1952, affiliated to McGill University’s Genetics Department; see http://biology.mcgill.ca/fraser.
html. For Victor McKusick, see biography on page 88–9. 
10  Professor Peter Harper also trained with Victor McKusick. 
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I’ve been trying to think, were these people particularly conscious of ethical issues 
and was there any particular aspect of practice that stands out? To be honest, 
I don’t think they were particularly aware, certainly they weren’t aware in any 
formal sense of ethics as a philosophical field.11 They were all good clinicians, 
experienced clinicians, and they were all what I would consider to be principled 
people, but I don’t think they were especially conscious of ethics as a particular 
field. I think that also goes for the people in Britain who were the founders: 
Cyril Clarke in Liverpool, Paul Polani at Guy’s, Cedric Carter and John Fraser 
Roberts at Great Ormond Street.12 Again, most of them, well three out of those 
four, were experienced clinicians. Fraser Roberts, I seem to remember Marcus 
Pembrey saying, he qualified in medicine and then hung up his stethoscope, 
and that was a reasonable thing to do because he wouldn’t have got the respect 
perhaps and the entrée without his medical qualification. But I don’t think any 
of them were formally conscious of ethical aspects. Cedric Carter, of course, was 
a proponent of eugenics but I actually don’t think that crept into his practice 
particularly. I think that he was, he behaved as, a principled person and I think 
this was why all these people were very well respected. 
I suppose really, just to leave things there, I don’t think ethics came in consciously 
at that early stage except, and it’s a very important ‘except’, that I think the core 
of people who founded the field of medical genetics were principled people, 
kindly people also, who were respected both by the people they saw in terms of 
patients and families, and by the people who trained and worked with them. 
This gave the area a sound foundation and a foundation, which was very much 
needed after what had happened before, and it’s that which I hope will be picked 
up on. Of course, you could say there weren’t very many practical issues arising 
in those early years that raised ethical aspects. That all lay in the future, and it 
will be interesting to wonder how they might have dealt with these. But it was a 
sound foundation, and I think one that needs to be recognized and I hope other 
people will be able to elaborate on that.
Lucassen:  Thank you, Peter. Can I just clarify, you say you don’t think those 
founding fathers were really involved in ethics. Do you mean in what you might 
call formalized, philosophical ethics, or do you think that actually the term 
11  Professor Peter Harper wrote: ‘Clarke Fraser, still active at age 97, has confirmed this for me in an 
email, November 2014, and refers me to his 1961 paper, “What it means to be a medical geneticist”, Fraser 
(1961).’ Note on draft transcript, 1 December 2014. 
12  See biographies in Christie and Tansey (2003) – the publication of a previous Witness Seminar to which 
Professor Paul Polani contributed. For John Fraser Roberts, see biography on page 85.  
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ethics has changed a bit over the years, and if they were sitting here now they 
would think they were as involved in ethics as we would say we are at the 
moment?
Harper:  I should think they would be very much involved, and indeed in their 
later years some of them were. Some like Paul Polani and others. So probably, 
yes, I think I was thinking of formal ethics. I perhaps would feel that they 
strongly subscribed to the Hippocratic Oath and that was the foundation of 
their practice. 
Lucassen:  Does anybody want to add to that? 
Professor Bernadette Modell:  I wonder whether part of what you’re saying is 
that they founded the field with a good basis in humanity. It strikes me looking 
back and remembering my own experiences as a paediatrician in the 1960s 
that there was a major, major ethical issue at that time, which was whether 
you did your best to encourage affected children to survive, or whether you 
thought it was a good thing that they died. I feel that there was an evolution of 
social attitudes around in favour of doing your best to look after and give equal 
quality of care to affected children. But I’m quite sure that that was not the 
general view in the 1960s and there were certainly some areas where it wasn’t 
in my own experience as a young house physician. So when you think about 
Figure 3: Professor Bernadette Modell
Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research
10
these founding fathers, can you think of any steps they made, or any explicit 
statement that one should care for affected people, or was it just implicit in the 
way they practised? I’m sure that was the case with Penrose because I remember 
when he came to give a talk in Cambridge and I was a student there. The whole 
talk was full of humanity, and it gave me a completely different perspective on 
Down’s syndrome.13 
Harper:  All I’d say to that, Bernadette, is that perhaps I’m not the best person 
to answer because I came into medical genetics from adult medicine, and the 
people I worked with, like Cyril Clarke and Victor McKusick, were essentially 
adult physicians where this didn’t arise in the same way. So I think others would 
probably be able to answer better.
Professor Marcus Pembrey:  I take issue a little bit with the distinction between 
people who did the best they could, Hippocratic Oath, and so on, but not 
embracing formal ethics. I still struggle with quite what you mean by that. But 
I think the main reason why it wasn’t dominant, and that we didn’t see chapters 
in Fraser Roberts’ textbook, for example, on ethical issues, was there was so 
little they could do.14 So there wasn’t the sharpness of the decision and, indeed, 
13  See, for example, Penrose and Smith (1966). 
14  Fraser Roberts (1940). 
Figure 4: Professor Angus Clarke, Professor Marcus Pembrey
Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research
11
I took the precaution of quickly reading the first edition I was involved in, 
1978, just to make sure that there were certain things in there. Indeed, there is 
a rather discursive short paragraph saying, if I paraphrase, ‘Of course, the final 
decision of what the couple decide to do, whether to take the risk of having a 
further child or a child, or even getting married, should be left to them.’15 That 
was there in the late 1970s, but there was a lot of emphasis on putting things 
in perspective, and there was an element of directiveness in the sense that it 
was important to clarify for them what was the background chance of any baby 
having a severe abnormality manifest at birth, or soon after, and then to put 
their own particular risk in relation to that.
Certainly, John Fraser Roberts would classify them into low risk where you 
should be encouraging, and the high risks where they would have to make a 
serious decision about it.16 So I think it’s partly that there was very little they 
could do. He even used phrases like, ‘It’s all rather fortunate that the less we 
know about the condition and its genetic underpinning the lower the risk, so 
that makes genetic counselling much easier.’ 
Lucassen:  Can I ask, what would you think then were the first group of 
conditions where you could do something about it that maybe raised different 
ethical issues, or began to raise ethical issues more?
Pembrey:  Well, I think the biggest one was prenatal diagnosis and selective 
termination of pregnancy. By the 1970s, of course, we had screening for neural 
tube defects and so on, and that’s when it became crystallized that one had to 
make very sure that it was the couple aided to make the decision that’s right for 
them rather than anything else.17
Professor Peter Turnpenny:  Just a small contribution on that point from my 
friendship with Professor Alan Emery over the last years. He did relate to me the 
story of finding that in neural tube defects alpha-fetoprotein was very high, and 
how they found it in the Edinburgh laboratories with David Brock. They came 
across the discovery and then asked the question, ‘Oh, what on earth do we do 
with this now?’, so I think it’s very much a case as we, I think, find all the way 
through, that actually it’s the science that leads the ethics. It’s the discoveries 
that ultimately then pose the questions. I think the same is true today. We can 
15  Fraser Roberts and Pembrey (1978), see page 292. 
16  See biography, page 85. 
17  For a review of screening for neural tube defects in England and Wales, see Cuckle (1994). 
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anticipate a little bit more today, with a very developed discipline of medical 
ethics, but I think it will always remain the case, probably, that you don’t quite 
know what’s around the corner until the science actually poses the questions 
for you.
Professor Martin Richards:  I just wanted to recount something about Paul 
Polani, which I’m having trouble in dating, but I think this must be the late 
1960s, perhaps early 1970s.
At that time there were some organizations, and I believe it was actually the 
Ciba Foundation that sponsored a series of public discussions aimed at medical 
students around ethical issues, and it was a kind of travelling roadshow that I 
was also involved in and went to, I don’t know, three or four different medical 
schools.18 Paul Polani took part in all this, and he would have been talking 
about prenatal screening and decision-making around that. I mean not formal 
ethics, but the point of those meetings was to raise the consciousness of medical 
students about ethical issues in medical practice, broadly speaking.
18  Professor Martin Richards wrote, ‘I don’t think this is right; possibly the sponsor of those discussions/
debates with medical students was the Nuffield Foundation. … [It is] important to note that the range of 
ethical/social issues in medicine were raised at these meetings were very wide and not just in relation to 
genetics, prenatal screening, etc.’ Email to Ms Emma Jones, 16 January 2015. 
Figure 5: Professor Peter Turnpenny
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Tansey:  May I ask, does anyone else remember those Ciba meetings? It would 
be very interesting to know how they were started, who got those going?
Richards:  They certainly had one in Bristol if that’s any help.
Tansey:  I’m thinking also of, say, the London Medical Group and the work the 
London Medical Group did on ethics.19
Richards:  That was the same kind of activity, yes exactly.
Professor Shirley Hodgson:  I was doing a little bit of homework last night, 
just like Marcus, because I was wondering what to discuss. So I went back to 
have a look at, for instance, things like the foreword to Lionel Penrose’s book 
on mental deficiency, ‘defect’.20 It was quite interesting that Haldane was saying, 
even in the late 1940s, that we should encourage people who had mental defects 
not to have children, and asking whether we would want to offer to sterilize 
them, and things of that sort, which we would find totally abhorrent now.21
I think it’s very easy to forget what the climate was in those days. There was an 
awful lot of feeling that we should not allow people who were not so intelligent 
to produce more children, and they were worrying that if they had more children 
19  For the London Medical Group, see Reynolds and Tansey (2007); pages 11–15 and Appendices 1–3. 
20  Penrose (1949); preface by J B S Haldane. Lionel Penrose was Professor Shirley Hodgson’s father. See also 
note 5.
21  For a discussion of Haldane’s views on politics, philosophy, and science between 1922 and 1937, see 
Sarkar (1992). 
Figure 6: Professor Martin Richards
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than more intelligent people, it would result in a drop of IQ in the population. 
In fact, Lionel, I know, spent a lot of time disproving that, and that there wasn’t 
a steady decline in the IQ of the population.22 So there was a huge climate of 
eugenics early on, and this was quite difficult to emerge from. I think that 
shouldn’t be underestimated: various countries were still sterilizing people who 
had mental defects and other problems, trying to prevent them from having 
offspring, so that had to be counteracted.23 I think there were the issues of trying 
to develop respect for people who did have ‘mental defect’, as they called it then. 
I know Lionel did do some clinics at the Galton, and offered genetic counselling 
and advice on a small scale. Lionel was saying, quoting Kevles in his wonderful 
book In the Name of Eugenics, that ‘a large number of the patients who sought 
genetic advice acted in a way that would be considered generally to be reasonable 
so they avoid risks which are serious and accept those which are only moderate’.24 
He predicted that the results of skilful counselling over a long period of years 
would undoubtedly be to diminish very slightly, but progressively, the amount of 
22  Penrose (1950). 
23  For a discussion of eugenics in the Scandinavian countries, see, for example, Roll-Hansen (1989), and 
Anon (1999).
24  Kevles (1985), page 258. 
Figure 7: Professor Bernadette Modell, Professor Shirley Hodgson 
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severe hereditary diseases in the population, based on their own decisions rather 
than doctors telling people what to do. So I think there was a gradual move from 
telling people what to do to allowing them to make their own decisions, which 
didn’t happen overnight: this was all happening in the 1950s to 1970s probably. 
Dr Alan Fryer:  Can I just ask Peter and my more senior colleagues a question 
about the great men of the past that Peter’s talked about. You’ve talked, Peter, 
about that, perhaps in their clinical practice, ethics may not have had a formal 
place. What about in research ethics? When I think of Victor McKusick and 
many others, there must have been some framework of research ethics in those 
days, even if not in clinical ethical practice. 
For example, all of Victor McKusick’s studies amongst the Amish and so on, 
there are the issues of how you approach people, and consent, and showing 
respect for the autonomy of people. These are strong ethical issues that actually 
permeate our specialty today, and have done certainly throughout my time in 
the specialty.25 I’d be interested in your comments.
Harper:  Well, I don’t think there was anything very fixed. I certainly can’t 
remember being aware of any research ethics committees, certainly not while 
I was in Liverpool at the end of the 1960s, or in America in the beginning of 
25  McKusick (1978). 
Figure 8: Dr Alan Fryer
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the 1970s. I think it was a much less tangible thing than that. Just to give an 
example, a Liverpool example for you, Alan: Cyril Clarke’s Rhesus study. I seem 
to remember him referring to this in a slightly teasing way, comparing it with 
an American study, which was going on at the same time,26 and saying that 
the Liverpool study on preventing Rhesus immunization, which was the first 
series, was carried out on volunteers who were local Liverpool policemen who 
all volunteered. I’m sure they didn’t have to sign anything in writing or anything 
but they volunteered. He would contrast this, I remember, with the American 
study, which was done on prisoners.27 [Laughter] He didn’t generalize from that, 
but, you know, that perhaps tells you something. 
Then, as far as Victor McKusick is concerned, of course, the clinical fellows 
working with Victor, of whom I was one at the end of the 1960s/beginning of 
the 1970s, we spent much of our time going out into the outback, and it really 
was outback, tracking down families with whatever. That was an extraordinary 
learning experience in terms of rural America, and the deprivation and poverty 
one encountered, but also of the welcoming nature and essentially, well, good 
nature that people showed, even when it was very clear, and one always tried to 
make it clear, one didn’t have much to offer. But it’s fair to say that in exchange 
what we did offer in these home visits, which took up days and weeks, was just to 
listen to people and hear about all their medical problems, and occasionally one 
was able to put them in touch with people who could be helpful. Victor himself 
was always very keen on making sure that the families got good treatment, 
which was pretty necessary for things like congenital heart surgery and other 
things, which they would never have been able to afford otherwise. He also 
worked very closely with the social scientists; in the case of the Amish, John 
Hostetler, who was of Amish extraction and had written a book on the customs 
of the Amish.28 Victor and all those people working on the Amish with him very 
much tried to keep in line with the customs and patterns of life of the Amish 
people, with the result that they were very welcome. The same with skeletal 
dysplasias – he was always very welcome, as were the fellows, at meetings of 
Little People of America.29 Because one tried to provide a bit of help as a quid 
pro quo. You couldn’t do very much but you did what you could, and the very 
26  Clarke (1968). 
27  See Zallen, Christie, and Tansey (eds) (2004), page 32. 
28  Hostetler (1980).
29  McKusick, Kelly, and Dorst (1973). 
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fact that you were often going out to see people rather than expecting them to 
come to see you was appreciated. I don’t think there was anything more formal 
than that, nothing that I can remember. 
Dr Nick Dennis:  From 1972 till 1976 I was Cedric Carter’s trainee at Great 
Ormond Street, which meant that I sat in on pretty well all the clinics.30 He 
didn’t allow me to actually do any clinics [laughter], but I spent a lot of time 
watching him do them. For him, it’s worth pointing out that he was primarily a 
researcher and it was the Medical Research Council (MRC) Genetics Research 
Unit. I didn’t have any sort of clinical appointment, I was an honorary registrar, 
I was also MRC-employed during that time, so for Cedric his clinical work was 
one afternoon a week plus ward referrals. He saw his job as giving an opinion 
and relaying that opinion back to the GP who would then negotiate, if necessary, 
with the family. 
He did have a marvellous woman called Kathleen Evans who was not medical 
by training, she was trained as a social worker, who sat in on the clinics. That 
was the beginning of what I think of, I suppose – I hope it’s not interpreted as 
patronizing – as a sort of feminine influence coming into clinical genetics. She 
30  Professor Cedric Carter (1917–1984) was Director of the MRC Genetics Unit from 1964 to 1982. He 
founded the UK Clinical Genetics Society in 1972. See Wolstenholme (ed.) (1989).
Figure 9: Dr Nick Dennis
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was one of the very early non-medical genetic counsellors.31 Consultations took 
about 20 minutes. If somebody required any further discussion because they were 
distressed, Kath Evans would go out and talk to them in the corridor and might 
very occasionally arrange to talk to them again later. I should just comment on, 
well, it seemed, during all my time with Cedric he was very firmly non-directive, 
and I think I would agree that although ethics was not talked about he had a 
strong personal ethic of respect for the individual and individual autonomy.32 
I think it’s worth just saying that people didn’t talk as much about feelings 
in those days, and it was a masculine specialty, as most specialties were, and 
so people kept their views about feelings pretty much to themselves. But I’m 
sure Cedric really believed that you shouldn’t tell people what to do, and I 
think he saw his role more as encouraging people who had a low risk, rather 
than trying to stop people with a high risk reproducing. As far as his eugenics 
was concerned, he did believe in eugenics, but he thought that if people were 
given information you wouldn’t need to tell them what to do because they 
would make sensible decisions. His eugenics was in relation to intelligence. 
He thought people with low intelligence only had a lot of children because 
they hadn’t got access to contraception, so he thought that if contraception was 
available that would take care of itself.
Lucassen:  They would be intelligent enough to use it, you mean?
Dennis:  Exactly, well, yes, I mean it’s a simple decision. And, as many of you 
know Cedric, had, I think, six children. 
Pembrey:  Seven!
Dennis:  It’s rumoured that his main criterion for selecting his wife was on the 
basis of intelligence. He did one day say to me, ‘How many children have you 
got, Nick?’ And I said, ‘Only one.’ And he thought a bit and said, ‘I think you 
31  Mrs Kathleen Evans was an almoner at Great Ormond Street Hospital for Children in the 1950s who 
became involved with family counselling at Cedric Carter’s genetics clinic; see Harper, Reynolds, and Tansey 
(2010); pages 28–30. 
32  Professor Martin Richards wrote: ‘There was a lot of discussion of C O Carter’s clinic. I don’t think there 
is any evidence that his practice was very different from anyone else in that period. He was a member of 
the Eugenics Society, as were quite a number of others in the field in that period. He gave advice to couples 
(wasn’t non-directive), including on reproductive matters. In the published follow up study, the authors 
assess the extent to which that advice was taken. Other follow up studies of other clinics throughout what 
we might call the pre non-directive period show the same approach.’ Email to Ms Emma Jones, 16 January 
2015. See also note 33. 
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should have another’, which I took as a compliment. [Laughter] The question 
of whether people took any notice of the risks in the clinic was to some extent 
answered by the famous follow-up study of Fraser Roberts and Carter, ‘Genetic 
clinic: A follow-up’, where it did turn out that people given low risks had more 
children than people given high risks.33 
Pembrey:  I’m very glad Nick’s told that about Cedric; that’s exactly I think 
what I would say. In terms of getting a handle on this shift fully away from 
a somewhat eugenic background, it was interesting that Cedric – this was in 
1979 but he’d had it in earlier books – felt that the long-term aim of genetic 
counselling was to see that as few children as possible are born with serious 
genetically determined or part genetically determined handicaps. He saw the 
goal quite explicitly as reducing the birth prevalence of these disorders, not 
necessarily by termination of pregnancy and prenatal diagnosis but restraint or 
whatever. I think he genuinely believed that if you gave them the information 
that consequence would follow. Things changed fairly soon after that with the 
WHO (World Health Organization) having a general statement, which was 
adapted a little bit for medical genetics to the goal of being to help those families 
with genetic disadvantage live and reproduce as normally as possible.34 There 
was a lot of discussion, of course, about what was normal but it was the shift 
from the reduction in the birth incidence to that reduction being a consequence 
of genetic services. 
Coming back to John Fraser Roberts, and it was in line with what Cedric thought, 
he genuinely believed that if you could give people as accurate information as 
possible and also to disabuse them of stories that they’d heard from relatives and 
so on, they’d often come with news, even members of the family, saying, ‘You’ve 
had two affected children, now you’re bound to go on having them’, and so on. 
He felt that what I would call therapeutic understanding was part of what they 
delivered, and I know that John Fraser Roberts did hang up his stethoscope 
and he put that in the context of not making diagnoses himself. He always got 
that done by a specialist, if possible, but he certainly believed within the clinical 
practice of clinical genetics in this therapeutic understanding, as it were. He 
believed that it was a real benefit in the broadest well-being sense to give them 
all the information in order for people to make their own decisions. 
33  Carter et al. (1971). 
34  World Health Organization (1985); see pages 25–8 for discussion of ‘ethical issues’ in genetics services. 
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Dennis:  There was something I’d forgotten, just one further brief point about 
Cedric Carter. Yes, in the early years when people would say, ‘What would you 
do, Doctor?’, he would never say. But in his later years, he felt that too many 
people were deterred by what were low risks, and if people said, ‘What would 
you do, Doctor?’, and it was a low risk he was prepared to say, ‘In your place, 
I’d probably take the risk.’ 
Lucassen:  I’m really interested in what some of you have been saying about 
there being no ‘formal’ ethics then. I wonder if someone can expand a bit on 
that and what do you mean by formal ethics, and when do you think formal 
ethics did come in? It sounds like, with what you’ve been describing about the 
founding fathers in genetics, that they had very strong ethical principles, so 
what is it then that is ‘formal’ ethics?
Harper:  Well, I won’t answer that, Anneke, or try to, but basically most of us 
going in as clinicians and coming out as clinical geneticists had absolutely zero 
grounding in philosophy, psychology, or any other kind of ‘ology’ really. What 
we knew we had either picked up through our experience in meeting patients 
and families, or the general principles we’d been brought up with. We’d no idea 
that all this had some counterpart in philosophy, or ethics, or humanities, and 
that’s something that I hope we’ll come to later on.35 I remember being really 
surprised and pleased when I was told, ‘Oh well, this is an example of whatever 
principle’, to learn that it actually had a name. [Laughter] I was a bit like a 
family who had been without a diagnosis for decades and suddenly realising, 
‘Well, what one’s been doing all these years, it isn’t just some way-out unskilled 
thing, it’s actually what seems to be a fairly appropriate practice and it’s got a 
name, which is respected among the humanities.’ I think that bucked up quite 
a few of us, learning that, yes. 
Turnpenny:  In the early 1980s, when the Childress and Beauchamp framework 
of medical ethics was published, namely the four principles of beneficence, 
non-maleficence, autonomy, and justice, which we quote an awful lot, and 
that came out close to the time that I graduated, so it didn’t really hit my 
consciousness at the time, that’s for sure, but we often talk about it and quote 
it and so on.36 Yet we know it’s not particularly helpful for aspects of genetics, 
especially the autonomy issues, but I just wonder if those who would have been 
35  For a Witness Seminar on the influence of the medical humanities in medical education, including 
medical ethics, see Jones and Tansey (eds) (2015). 
36  See Beauchamp and Childress (1979). 
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more aware of it being introduced at the time, whether that was a stimulus to 
think about its application to medical genetics.
Modell:  Looking back, I want to ask a question. Of course the concept, the 
word ‘ethics’ wasn’t commonly used in the medical framework when I was a 
young doctor, but the first time it came above the horizon for me was with the 
organization of research ethics committees and then suddenly the whole issue 
became important to anybody who was interested in research.37 I just wonder 
whether the formalization of the ethical principles arose from that. The second 
point I want to make following on from yours, was the work of Fletcher and 
Berg and Tranøy. They did a survey of practising clinical geneticists, asking a 
series of targeted questions to elicit their ethical values.38 That must have been 
late 1970s. The three key principles within medical genetics of autonomy, full 
information, and confidentiality emerged and were so crisply presented that 
they were useful guiding principles. 
Lucassen:  My impression is that we are confusing, or overlapping, different 
types of ethics: what is formal ‘ethics’ and what are neatly articulated ‘principles’? 
Research ethics appears to be rife with neatly articulated governance principles 
but what we’re trying to get at here is more how ethics entered clinical practice. I 
don’t see that as formal or informal really, so are we using different terminologies? 
Richards:  Can I bring in a slightly off-side comment? Something I’ve been 
interested in writing about recently is the governance of assisted reproduction.39 
I’ve been reading a lot of material in discussions about infertility, about using 
donor sperm and all of those things, and what you do see in those discussions 
is in the, I suppose, late 1960s if you look at let’s say the discussion at the Ciba 
Foundation of those issues that took place, there’s a single person who always 
turns up, who is Gordon Dunstan.40 He seems to me, he was a kind of one-man 
ethics person. 
37  See, for example, Emanuel et al. (eds) (2008). 
38  Fletcher, Berg, and Tranøy (1985). 
39  Richards (2016). 
40  Revd Professor Gordon Dunstan (1917–2004) was Secretary of the Church of England Council for 
Social Work from 1955 and a minor canon at St George’s Chapel, Windsor, and then at Westminster Abbey, 
London. He was secretary to the group that prepared a report for the 1958 Lambeth Conference, which led 
to the acceptance of contraception. He was the first holder of the F D Maurice Chair of Moral and Social 
Theology, King’s College, London (1967–1982), later Emeritus, and Chaplain to the Queen (1967–1987). 
For an obituary, see Shotter (2004). 
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Lucassen:  There’s a lot of nodding around the room, yes.
Richards:  And I think he, through those discussions, he was always there and 
he would always bring up the ethical issues, that’s what he was invited to do. I 
mean that was his role in those groups. 
Lucassen:  But who invited him to do that?
Richards:  Everyone. If you look at the formal membership, for example, of 
the British Medical Association committee, he’s everywhere, always the same 
person. I and others who were around then, I guess the first thing we ever learnt 
about ethics was listening to him.
Modell:  Did he found the first course in King’s College on medical ethics? Is 
that why he was so recognized, so influential? Do you know when?
Lucassen:  Elizabeth, behind you, I think might know. It looks like she knows.
Mrs Elizabeth Mumford:  I taught on the first course on medical ethics. Ian 
Kennedy was the director of that course and he is probably an interesting 
person to bring in at this point. Ian Kennedy was at that time a professor of 
law at King’s College, London. He gave the Reith Lectures on the ‘Unmasking 
of Medicine’ in 1980.41 My time at King’s College began in 1984, and that was 
41  The six Reith Lectures given by Professor Ian Kennedy can be heard or downloaded at www.bbc.co.uk/
programmes/p00h2dg1 (accessed 4 June 2015). 
Figure 10: Mrs Elizabeth Mumford
Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research
23
the year Ian Kennedy started, what I believe was the first postgraduate course in 
medical law and ethics at King’s, bringing together people who were graduates 
in medicine, law, philosophy, and all sorts of other areas to study these issues.42
Reverend Professor Gordon Dunstan had retired by that time, but he had 
been very much involved in the development of the Centre of Medical Law 
and Ethics at King’s, which had been founded a few years earlier, and he often 
came back to visit. That’s certainly how I met him, but he didn’t actually 
teach on the course.43 I think it’s interesting to consider that, while there 
were interesting things developing in medical ethics in the late 1970s and 
early 1980s, there were also significant developments at the same time in 
medical law. I think that was no coincidence; the two came together. The first 
textbook in medical law and ethics that I remember using was Mason and 
McCall Smith – the first edition was published in 1983 – the now-famous 
novelist Alexander McCall Smith.44 
Pembrey:  Yes, I absolutely want to concur about Gordon Dunstan, certainly 
in the London scene anyway, being the person who was always there on hand. 
He was Professor of Moral and Social Theology at King’s, and I sat on the 
same ethics advisory committee of the British Paediatric Association, before 
it was a college, from 1988 to 1995. He was also on that committee and was 
a huge guidance. I remember, particularly, I asked him what was his personal 
guiding moral compass – as we would say these days, we didn’t use that phrase 
in those days – and he said, ‘principled pragmatism’, and ‘you go down to the 
clinic’. I can hear him saying it: ‘You go down to clinic with your principles, 
but you’re probably going to have to make a pragmatic adjustment.’ That’s 
why I put it in the heading in a chapter of a book I wrote, because it was in 
honour of this approach.45 
42  For the postgraduate course at King’s, see www.kcl.ac.uk/law/research/centres/medlawethics/index.aspx 
(accessed 4 June 2015). 
43  Mrs Elizabeth Mumford wrote: ‘When the postgraduate diploma (later MA) course began, Ian Kennedy 
gave the law lectures. I was the tutor. The ethics lectures were taken first by the Oxford philosopher, 
Dr Michael Lockwood, then later by Dr Raanan Gillon, who was by then the editor of the Journal of 
Medical Ethics. Both of them were writing books on medical ethics at the time.’ Note on draft transcript, 12 
January 2015. Lockwood (ed.) (1985).
44  Mrs Elizabeth Mumford wrote, ‘[He] was originally a well-respected academic lawyer.’ Note on draft 
transcript, 14 January 2014. Mason and McCall Smith (1983). 
45  Pembrey and Anionwu (1996), pages 641–53.
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The other thing I particularly remember about Gordon Dunstan was that he 
said: ‘The key thing is don’t get muddled between bad practice and ethical 
issues; bad practice, if everybody agrees, is just that some are not sticking to 
what is agreed. Real ethical dilemmas are two opposing or conflicting views, 
both of which are justified and you have the tension between them.’ And then 
he always followed it up by saying: ‘So long as that tension remains, we are 
safe and probably morally attuned, as it were. It’s when there isn’t any tension 
that one should be alarmed about these things’, and those are the two things I 
particularly remember about him; wonderful man. 
Richards:  He, I know, was a fellow of at least two of the royal colleges, so I mean 
he was sort of incorporated into the medical world in that sense.
Lucassen:  I wonder if someone like Nina, Michael, or Bobbie wants to comment 
on this discussion about clinicians not engaging in formal ethics and pragmatism 
and things like that? What do you think listening to this discussion? 
Professor Bobbie Farsides:  I was very interested by what you said about the 
roots of non-directiveness lying in a confidence that giving the information in 
and of itself would lead people to make good decisions, because that’s rather 
a different set of roots for the practice than I might have assumed from the 
outside. I wonder if things had to become a little bit more challenging when 
you started to face choices about not just whether or not to have children within 
an affected family, but also about the termination of pregnancy.
Figure 11: Professor Bobbie Farsides
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Then non-directiveness becomes a way of almost putting a barrier around a 
different moral decision and leaving that with the individuals, whereas, initially, 
if you felt that giving the clinical facts about the risks involved was the essential 
information that people needed to make decisions, maybe clinicians felt safer 
doing that. 
Lucassen:  So you think the distinguishing thing would be what could be done 
about those two? Have I got that right?
Farsides:  Yes, and why non-directiveness then became such a fixed principle, 
because it was actually marking out different territory. It wasn’t about explaining 
risk, it was actually about getting involved in moral decisions about termination 
of pregnancy.
Lucassen:  That’s very interesting. Of course, as genetic practice has gone on, 
there have been more and more things that we can do something about, so that 
would explain that shift to some extent. 
Professor Michael Parker:  Because it’s a Witness Seminar, I don’t want to talk 
about things I haven’t witnessed myself but just to report a story. I think it’s 
quite important that many of the figures in medical ethics, Raanan Gillon, Tony 
Hope, Alistair Campbell, and so on, when they’ve spoken to me about it, they’ve 
talked about the London Medical Group, the student medical ethics groups in 
Figure 12: Professor Michael Parker 
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London, which spread to Oxford, as being very foundational for them.46 Many 
of them were doctors. Leading to the introduction of medical ethics in medical 
training, I know there was a campaign by that group of people, which led up 
to Tomorrow’s Doctors, the GMC (General Medical Council) report in 1992 or 
1993, which said that ethics and communication skills had to be core elements 
of every course of every medical school.47
So there is clearly a story to be told there. I mean, it seems obvious that ethics in 
some form was taught and has been part of medical practice for a long time, but 
it was around about that sort of time that it started to be a formal requirement 
across the UK; that is my understanding at least. 
Hodgson:  I agree. I think it’s very interesting that the idea of ethical discussions 
being part of the way you dealt with patients is terribly important, but I still feel 
there was also this climate of telling people what to do and trying to improve the 
race, which was still going on in the early 1950s, and certainly the 1940s, that 
people had to escape from.48 There was an evolution, I guess, from instructing 
people about how they ought to behave to allowing them to make their own 
decisions, and it must have been quite a release, the feeling that you could 
allow people to decide for themselves. Non-directiveness was then the right way 
forward, which probably came with the ethics principles. 
Dennis:  I’ve just thought of something, which was a book by Pappworth called 
Human Guinea Pigs, and that for me was influential – I qualified in 1968 and I 
think we had no discussion of ethics in my medical training at all – I think this 
came out about the time I was working for Membership. Have other people 
heard of this book? 49 Yes.
46  Professor Raanan Gillon (b. 1941) was a general medical practitioner, philosopher, Director of the 
Imperial College Health Centre, Editor of the Journal of Medical Ethics (1980–2001), and author of the 
book Philosophical Medical Ethics; see Gillon (1985). Professor Tony Hope (b. 1951) is a psychiatrist who 
led the Oxford Practice Skills Course, and was Director of Ethox, Oxford, from 1999 to 2005; see Hope, 
Fulford, and Yates (1996). Professor Alistair Campbell (b. 1938) was Associate Chaplain to the University 
of Edinburgh (1964–1969) and Lecturer in Ethics at the Royal College of Nursing (1966–1972), Scotland, 
when he wrote the first modern textbook in medical ethics; see Campbell (1972). Professors Gillon and 
Campbell contributed to a previous Witness Seminar on the history of medical ethics education in Britain, 
and have biographies in the published volume, as does Professor Hope, whose work was also discussed; 
see Reynolds and Tansey (eds) (2007). See also note 43. 
47  General Medical Council, Education Committee (1993). 
48  See Hanson (2013). 
49  Pappworth (1967).
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Pembrey:  It was to do with the Hammersmith, wasn’t it?
Dennis:  It was about research ethics basically, and I think that raised the 
awareness of ethics in people like me, young doctors, enormously. The other 
thing that did that in a slightly different way was a book, which was given to me 
by a fellow medical student who ended up as a professor of medical sociology, 
so that probably indicates his leaning at the time, and it was called The Doctor, 
his Patient and the Illness, and I’ve forgotten what the name of the author was; 
it was by Michael Balint.50 That just opened up another way of thinking about 
the medical consultation, which you wouldn’t have got from, you know, going 
to Thomas’s and doing your clinical training there.51
Lucassen:  I think that leads quite nicely into a discussion about presymptomatic 
and predictive genetic testing and the issues that that brings up, and perhaps 
how it is different from other clinical practices. We’re fast-forwarding quite a 
few years on from the earlier discussion, when genetic tests became available 
that predicted something in the future. So Huntington’s, I think, would have 
been one of the first examples of a predictive genetic test, in the early 1990s.52 
I suppose, before that there was linkage for quite a few years, but then actual 
direct tests to predict something that’s going to happen in 10 to 20 years’ time 
came in. That is, I think it still today remains, a core feature of clinical genetic 
practice. It’s quite different to other clinical practices, and I don’t know if people 
want to talk about that and the ethical issues that that raises. 
Harper:  I was rather hoping that one or two people might expand a bit on this 
non-directiveness and how did it come in because again this was something that 
wasn’t there particularly at the beginning.53 Then it became an absolute tenet.
Lucassen:  And then it faded again.
Harper:  Well, it has not so much faded but people have realised that it’s not 
something that’s set in stone.
Lucassen:  Yes. And that’s quite interesting to relate also to the predictive testing 
because it comes in very much for Huntington’s, doesn’t it?
50  Balint (1957). 
51  St Thomas’s Hospital Medical School. 
52  The gene for Huntington’s disease was identified in 1993; see Huntington’s Disease Collaborative 
Research Group (1993).
53  Clarke (1997a). 
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Harper:  It does.
Lucassen:  It moves away again for the conditions where there’s perhaps more 
that can be done. So, yes, I think that’s very interesting. 
Professor Angus Clarke:  By the time I was in medical genetics I feel that non-
directiveness was fairly well established in the clinical genetics setting. What I 
found distressing, and why I cathartically put stuff down on paper was because 
of antenatal screening and what one could see going on there, where people 
were put into a context where it was very difficult to say no to what they were 
being led to comply with.54
Lucassen:  Can you give an example of what you mean?
Clarke:  Well, people booking in for pregnancy and it just being the automatic 
next thing to do would be to have serum screening or ultrasound or whatever. 
There’s less of it now, but arguably there’s still some of that, and I think it’s 
very difficult for midwives booking in pregnant women to have a deep and 
meaningful, and sustained, conversation with every woman about all the various 
choices they are going to be making many times a day with new people they 
don’t know. I think it’s very natural that people step back a bit from that, and, 
unless you do, I think the structure of that sort of clinic leads people to go along 
with the next thing. I feel that’s quite separate from what goes on within clinical 
genetics and the predictive testing and so on. 
54  See, for example, Clarke (1997b).
Figure 13: Professor Angus Clarke
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Lucassen:  Sorry, I’m probably being a little bit slow here but are you saying 
that’s an example of directive counselling, when the next step is obvious? 
Clarke:  Not directive counselling but more directive structure to the healthcare 
system that people are coming into. I mean, within those settings there will be 
some staff who maybe reinforce it and others who backpedal a bit and try and 
give people more choice, so there’s staff variation but just the structure of the 
process, I think, is somewhat directive.
Dr Nina Hallowell:  I do feel like a bit of a witness because I’m an outsider and a 
social scientist, and it seems to me that there’s been a very big change in terms of 
ethics within clinical practice, or non-directiveness in presymptomatic testing. 
So, for example, I can remember getting into this when I worked with Martin 
Richards in Bruce Ponder’s clinic in Cambridge, his breast and ovarian cancer 
clinic.55 At that time, the way in which clinics practised was, actually, everyone 
55  Dr Nina Hallowell wrote, ‘Sir Bruce Ponder ran a clinic in Cambridge at Addenbrookes Hospital with 
Dr Charis Eng in the early 1990s, partly to recruit people to studies they were initially undertaking to 
find BRCA1 and BRCA2 mutations. As I understand it Bruce was particularly interested in ovarian cancer. 
Martin Richards will know more about this – ah he says this below! I joined the Centre for Family Research 
at Cambridge University in January 1994 on a MRC-funded study which looked at families and genetic 
disorders; this looked specifically at late onset disorders – breast and ovarian cancer and Neurofibromatosis 
1. We became involved in Bruce’s clinic as they were particularly interested in the ethical aspects of these 
consultations, namely how to provide women with information so they could make informed decisions 
about risk management.’ Note on draft transcript, 6 December 2014. 
Figure 14: Dr Nina Hallowell
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was following the model that had been developed for Huntington’s disease. If 
you look at the way this has developed, it was very, very much ‘we must be very 
non-directive in these clinics, women must be given all the information and 
they must go away and make up their minds’, and now there has actually been a 
very big swerve to being much more directive about certain things, for example, 
risk-reducing surgery, chemoprevention, and breast screening.
Genetic testing for breast and ovarian cancer now takes place sometimes when 
women are diagnosed with cancer, so they may make a decision about adjuvant 
treatment or contralateral risk-reducing breast surgery, with very little of the kind 
of original model of the non-directive predictive-testing counselling. So it seems 
that there has been a very big change in the way that counselling is practised in 
the case of late onset cancers, and certainly the degree of non-directiveness in 
those kinds of consultations about cancer genetics these days.56 
Lucassen:  And what would you ascribe that to?
Hallowell:  I think it’s very much to do with the way in which the technology 
has changed, it’s the way in which actually the people who come to the clinics 
have very different expectations, they have more knowledge of genetics, and 
those kinds of ethical issues are actually much more understood by the public, 
the patient groups themselves.57 It’s become much more of a mainstream 
occupation, I think.
Lucassen:  Would you also think that it’s due to the treatments available? I think 
for Huntington’s we’d still have those prolonged sessions.58
Hallowell:  Absolutely, absolutely, definitely. I think at the very beginning, 
in cancer genetics consultations everyone was very worried about how they 
might deal with this group of women. A lot of them were very worried, it was 
very new, the women themselves didn’t know much about it, the press had a 
very particular take on it, and the clinicians were quite worried about how to 
56  See, for example, van Dijk et al. (2003). 
57  For the impact of media exposure of cancer genetics on the public, in the case of Angelina Jolie, for 
example, see Evans et al. (2014). 
58  Professor Anneke Lucassen elaborated, ‘Whilst I agree that consultations may have become more directive 
for conditions where there are treatments and interventions available (e.g. inherited breast and bowel 
cancers), for conditions where this is not the case (e.g. Huntington’s disease), non-directive counselling over 
several sessions is still very much aspired to. So it might be less to do with technology of the testing moving 
on, and more with the condition in question.’ Note on draft transcript, 20 September 2015. 
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actually deliver the services. They followed the best practice that was available 
at that time for predictive testing, which was the Huntington’s practice, and 
then they realised that perhaps we can actually develop this service and I think 
the technology and the preventive measures that women can take have really 
impacted on that. There has been a lot of impact from everywhere and it has 
changed what is perceived as perhaps an ethical issue in this sphere.
Farsides:  I was going to say much the same as you. I think the two cases are 
different because of the relevance of information. In the first case it’s what will 
or will not happen to you in the future, but in the second case it has now 
become part of getting the most effective treatment and that, in a sense, takes 
the heat off the information and makes it a different sort of transaction, almost 
to collect and provide that information. I was interested to hear from those 
who were involved in the early days with the Huntington’s testing. I wondered 
whether it was a surprise that people were so reticent to take the tests, or whether 
those of you with experience could have predicted that, because I’ve worked 
with the Huntington’s Disease Association, and have been to meetings with 
young people from affected families, and there’s still an enormous amount of 
ambivalence about having possession of that information.59 
Harper:  Yes, well, maybe things have come back to Huntington’s, and I was 
thinking before this meeting about how, not so much presymptomatic testing 
began, but what was the background to it? And one of the things is that the idea 
has been around an awful long time, and I went back to Julia Bell actually. In 
1934 in her monograph on Huntington’s disease, as part of the Treasury of Human 
Inheritance, she says: ‘… the almost continuous anxiety of unaffected members 
of these families over so long a period must be a great strain and handicap even 
if they remain free from disquieting symptoms. It is thus of urgent importance 
that some means should be sought by which immunity of an individual could 
be predicted early in life’; and she goes on to say: ‘Development of the science 
of genetics may at some future date enable us to obtain information concerning 
the inherent characteristics in such cases.’60 
That’s 80 years ago, and then I remember going to meetings that were 
always, and as far as I know may be still, biannual meetings involving the 
World Federation of Neurology research group on Huntington’s and the lay 
59  For further details of Professor Farsides’ engagement with the Huntington’s Disease Association, see 
Farsides (2011). 
60  Bell (1934–1947); vol. 4, part 1, ‘Huntington’s Chorea’, page 13. 
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Huntington’s societies. I think the fact that they were joint meetings was really 
helpful, but for many years, and I’m talking now about the 1970s and early 
1980s, people were looking ahead: ‘What if we could predict and how would 
we, how should we handle it?’ There was a series of semi-clinical approaches 
and neuroscience approaches suggested, none of which turned out to be valid, 
but they actually gave an important dry run for prediction when it did become 
possible. So it was 1983 when the first linkage, using DNA markers, was found 
and that meant firstly that people had already been thinking about it.61 When 
I say people, I mean neurologists and geneticists involved in Huntington’s and 
the lay societies involved with Huntington’s. People had been thinking about it 
and not coming to any conclusions, and it was during that era that a number 
of surveys were done of family members along the lines ‘if there was a test 
available, would you like to have it?’ Those surveys mostly showed well over 
50 per cent would have it.62 It was very interesting when it did become possible, 
we in Wales and others rapidly found that, in fact, a large number of those 
people who might have wanted it when it wasn’t possible didn’t want it when 
it was possible. That alerted us to some of the other problems. The other thing 
about the DNA linkage was that it was much closer than anybody had any right 
to expect, so it meant that practical use could be put to this linkage quite a long 
time before anyone had expected this, so it was a very good thing that it had 
been discussed a lot.63
Then the other thing, which I think perhaps explains why Huntington’s has 
been very much a paradigm, was that there was already a tradition of pooling 
data internationally and groups would get together and pool data on this and 
that, and so when prediction became feasible everybody pooled their experience 
both on the results and on problems encountered, and that meant that one 
could get really rather robust data from the sheer numbers involved on what 
problems were being encountered, because people were expecting serious 
problems. There was a real fear that people, if they’d had an abnormal test, 
might go out and commit suicide, and it was only the hard data that showed 
that that was very rare indeed. So Huntington’s, I think, led the way, partly 
because of the links between professionals and lay groups, partly because of this 
tradition of pooling the data, and also because I think it showed up most of the 
problems and difficulties as a sort of worst case scenario. I was saying to some 
61  Gusella et al. (1983). 
62  Evers-Kiebooms, Cassiman, and van den Berghe (1987).
63  See, for example, Harper, Morris, and Tyler (1991). 
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people earlier that we, like the other groups involved, rapidly met a number of 
difficult ethical and practical problems, and my rather naive reaction to this 
was, ‘Well, we can’t get away from these problems, let’s make the problems the 
main aim of the study and then even if they’re still problems, at least we’ll have 
interesting data.’ People will learn more from the problems, and how we did 
or didn’t cope with them, than they will from the actual results. So by the time 
familial cancers came on the scene in the 1990s there was a good body of data 
from Huntington’s, even though it wasn’t really exactly the same situation, there 
was a good lot that was either the same or quite similar and you could use it as 
a starting point.64 
Richards:  That’s very interesting, Peter, but I’d like to make a comment about 
something else that was going on, which was actually, I think, almost completely 
disconnected from what you’ve talked about, and that is our experience and 
getting into work with Bruce Ponder.65 When he arrived in Cambridge, we’d 
already begun to be interested in some of these issues around testing in clinics 
and so on. I got a phone call from Bruce one day because he had set up a clinic 
simply for the families; he was collecting these families, doing linkage studies, 
and came to the conclusion he would have to give them, as it were, some kind 
of clinical support. So he set up this clinic and he basically didn’t know quite 
what to do in the clinic, quite literally, and he went to see Martin Bobrow one 
day and said, ‘Look, I need help’.66 He, for whatever reason, answered, ‘Go and 
see us guys’ – our Centre for Family Research.67 And we started working with 
Bruce in that clinic, which led us to extend our work into the field on inherited 
cancer syndromes.68 I think what was so striking about it was he was completely 
outside, if you like, the culture of clinical genetics. He was an oncologist, he 
64  For familial cancer susceptibility, for example, in 1991 the familial adenomatous polyposis gene was 
identified; see Groden et al. (1991); in 1994 BRCA1, one of the inherited breast and ovarian cancer genes, 
was identified by Miki et al. (1994); in 1993, a gene for hereditary non-polyposis colorectal cancer, MSH2, 
was identified; see Fishel et al. (1993) and Leach et al. (1993). For further discussion of familial polyposis 
and colorectal cancer, see, for example, Jones and Tansey (eds) (2013). 
65  From 1989, Professor Sir Bruce Ponder was Director of Cancer Research UK’s Cambridge Research 
Institute, now Emeritus Professor. He was Founding Director of the Cambridge Cancer Centre. 
66  Martin Bobrow was Professor of Medical Genetics at Wolfson College, University of Cambridge from 
1995 to 2005, now Emeritus. 
67  The research group focused on clinical genetics and families at the University of Cambridge that Professor 
Martin Richards founded in 1967 and directed until 2005. See Marteau and Richards (1996). 
68  See, for example, Hallowell et al. (1997). 
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was kind of inventing the rules from scratch, as I think was true for some of 
the other oncologists who were doing the same thing. They were setting up 
family cancer clinics for families with inherited cancer syndromes, but this 
was outside the orbit of clinical genetics. Indeed, at least in the beginning, 
they were not in contact with clinical genetics, which, looking back, I find 
rather surprising. 
Pembrey:  Could I just come back a little bit to the transition to non-directiveness 
at least being the stance, if I can use that phrase, for clinical genetic practice. My 
own experience was, I was involved in doing research on sickle cell disease and 
so on, and my first tour in America was in 1976. Following the words that John 
Fraser Roberts uses, ‘genetic advice’, when I was giving my talk and then we got 
onto counselling and I said, ‘genetic advice’, there were howls of dissent.69 So 
I learnt very rapidly the word ‘advice’ wasn’t right. I pleaded, ‘Advice: you can 
take it or not.’ But they didn’t buy that. That was my first taste of how strong 
certainly that group was in America. Of course, there was the whole question of 
screening for, and the lies about the number of people with sickle cell disease in 
Congress, and actually they used the figure for the sickle cell trait and so on to 
get money into the system. Then, when it came to DNA analysis, we were the 
first to get a close genetic probe for haemophilia A and were offering prenatal 
diagnosis for that and so on. We wrote the first paper in 1984 and then we 
wrote up our first clinical experience of using it in the BMJ (British Medical 
Journal ) in 1985.70 
Over the ensuing years we built up quite a series of family workshops to 
allow prenatal diagnosis, and when presenting our series in talks it was with 
considerable relief that we could report that one couple had gone for prenatal 
diagnosis but had changed their mind and decided not to have a termination 
of pregnancy. We always tried to say that, of course, you know you can change 
your mind at any time, it wasn’t an inevitable ratchet, and that was a big change 
because there were people at the time saying, ‘Well, there’s no point in having 
prenatal diagnosis if you’re not going to terminate the pregnancy.’ 
Lucassen:  We’d still say that now probably. 
Pembrey:  But, for me, non-directiveness is to allow them to have the prenatal 
diagnosis in case they change their mind the other way.
69  For John Fraser Roberts, see biography on page 85. 
70  Harper et al. (1984); Winter et al. (1985).
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Hodgson:  Actually, you’ve touched on a couple of things that are very interesting. 
Of course, one is the prenatal testing because one could ask whether you’re being 
non-directive to the fetus or non-directive to the parents, because the fetus 
might want to have a say in the matter as to whether they’re told whether they’re 
going to get cancer or something later on, so if the parents don’t terminate an 
affected pregnancy obviously this is an issue. But that’s another concern. The 
other thing is the issue of genetic screening. There was, as you said, the sickle 
cell screening in America, with the misconception that people who had the trait 
were actually affected, and people who had been screened were feeling that they 
had been stigmatized.71 
Clarke:  I just wanted to come back to the predictive testing situations, thinking 
particularly about the coming of, or the prospect of, therapeutic benefit. Then, 
in a sense, as soon as there’s a whiff of that, that sort of trumps non-directiveness 
so that medical people feel, ‘Well, it’s obvious, so now you’ve got to do this.’ 
The issues have changed over the years. There’s now the situation of people 
who are resisting being tested when it’s medically obvious that testing would 
be helpful for their medical management, and they’re maybe not always being 
given enough time to adjust to their situation and so on. I know that’s bringing 
it more up to date and so maybe it’s a red herring from a history point of view, 
but the issue has changed in a rather interesting way.
Lucassen:  One of the things I was thinking as the discussion was going on 
was that I’m still struck by how often people’s initial wishes are different to 
their more considered wishes. So they come in wanting one thing and then, 
when you have the opportunity to talk to them about it, they actually decide 
something else and, of course, Huntington’s predictive testing is quite a good 
example, because still far less people eventually have the test than who initially 
ask for it. Quite often they come in saying, ‘Well, I want a test’, but once they 
know all the pros and cons they say they will not have it. I’m interested to know 
how that relates to non-directive counselling, the difference between the initial 
and the considered decision?
Clarke:  You can be directive about the process in the sense of saying, ‘Well, we 
won’t do the test today.’
Lucassen:  Straight away, yes. 
Clarke:  But, you know, it’ll be your decision but we’ll set the pace a bit.
71  Markel (1992). 
Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research
36
Lucassen:  We’ll set the pace because we know from experience that you might 
change your mind.
Clarke:  But it’s a bit paternalistic, isn’t it?
Lucassen:  Or maternalistic even. 
Clarke:  But not about the outcome of the decision.
Lucassen:  Yes, yes. I’m interested to know what other people think about that. 
Farsides:  I was just going to go back again, sorry, to antenatal screening and 
testing, because in 1999 Priscilla Alderson and I were given the very first 
Wellcome Trust bioethics grant to look at antenatal screening and testing.72 We 
rather grandly called our project ‘The New Genetics in the New Millennium’.73 
We thought we would go in and talk to people about how genetic advances 
were going to change the terrain in terms of antenatal screening and testing 
and what was this new future that they needed ethically to prepare for. We 
were slapped down pretty quickly and told that people didn’t really want to talk 
about that, they wanted to talk about what they were doing at the moment, 
which was routine screening and testing for Down’s syndrome because they 
still felt there were so many unresolved ethical issues within that.74 And 
non-directiveness was one of the things that we ended up looking at. I thought 
one of the most interesting features of that was, while people could see the 
rationale for not being over paternalistic, and not pushing people along a 
conveyor belt, they were also aware that at certain points if they stood back 
and refused to be directive or refused to answer direct questions that could be 
perceived as being directive – their patients or the women they were working 
with felt abandoned by them.75 So there was a real sense of letting people down 
by adhering to something that had sort of noble intentions but actually might 
stop you assisting someone in their decision-making when they felt that they 
needed it most. 
72  Priscilla Alderson is a sociologist of childhood, and has worked at the Social Science Research Unit of the 
Institute of Education, University College London where she is Professor Emerita of Childhood Studies; 
www.ioe.ac.uk/staff/SSRU_2.html (accessed 24 June 2015). 
73  See Alderson, Williams, and Farsides (2001). 
74  Williams, Alderson, and Farsides (2002a). See also Williams, Alderson, and Farsides (2002b). 
75  Williams, Alderson, and Farsides (2002c). See also Williams, Alderson, and Farsides (2002d); and 
Williams, Alderson, and Farsides (2002e). 
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Lucassen:  I wonder if we can move on? I think this discussion lends itself quite 
nicely to thinking a little bit about consent and confidentiality issues raised by 
genetics. If we go back to Huntington’s as an early example of maybe testing 
somebody at 25 per cent risk when the person at 50 per cent risk doesn’t want to 
know, how do we manage the tensions that raises in consent and confidentiality?
Harper:  Well, since you bring up Huntington’s and the 25 per cent risk situation, 
it wasn’t something I’d thought would come up today but I do remember it 
causing a lot of quite agonized discussions in various forums. And the upshot 
was that two groups, our own in Wales and a group in Leiden, looked over our, 
by that stage, very large series of several hundred requests for prediction, and 
what we found was that requests for people at 25 per cent only made up a small 
proportion and that for most of those there weren’t major issues because the 
intervening parent was no longer living or because they were quite comfortable 
about things.76 And so there was the really difficult question of what do you do if 
a person at 25 per cent risk wants to be tested but the intervening parent doesn’t 
want to or something like that? Both our studies found, I think, either one or 
two examples of that and almost invariably what was a genuinely very difficult 
situation could be got round by good counselling and preparation beforehand. 
Both our groups concluded from that that there wasn’t any point issuing grand 
guidelines about what to do in such a situation because it was a bit like enacting 
a law for something that is very, very rare and occasional, and it’s going to cause 
more trouble than it solves. 
That was an example of how useful these large data sets were in coming to what 
was a very pragmatic conclusion, which was you should spend most of your 
energy not getting into that problem in the first place, and that the occasions 
when you can’t get out of it are too rare to try and generalize from and it’s 
probably better to do it on a case-by-case basis. 
Lucassen:  I suppose I’d thought of consent and confidentiality as a more general 
issue, of it raising communication within families in a way that, again, other 
specialties don’t do quite so much, although they, of course, also do. 
Parker:  I’d like to say lots of things about the stuff you just mentioned but I’m 
quite interested to ask a question. One of the things that Marcus talked about 
earlier raises the question: what’s an ethical problem?77 Is it only an ethical 
76  See, for example, European Community Huntington’s Disease Collaborative Study Group (1993). 
77  See page 24. 
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problem, you were quoting someone else, when people disagree, or can there 
be an ethical problem when people agree? And one of the things that struck 
me when I first got into thinking about ethical issues in genetics, which was 
in the late 1980s and 1990s, was the extent to which there was disagreement. 
So far we haven’t really touched upon that, and it seems to me that there’s 
disagreement between individuals sometimes but also between different 
regional genetics services. 
Also, the point about consent and situations where someone wants a test and 
there are other people at 25 per cent risk, because I’ve personally found there to 
be a lot of disagreement, and certainly historically when I first started. Both sides 
of this discussion took the view that ultimately you’d try to encourage, initially 
you’d encourage family members to talk to each other, but the differences 
emerged when that wasn’t possible, when people didn’t want to do that. There 
were some people who felt, ‘Well, ultimately the person in front of you is the 
person you should be taking care of and they should get access to the test, 
and other people shouldn’t have a veto over that.’ But there were other people 
who felt it was really important not to test other family members without their 
consent, and had worries also about how they might hear about the information 
and the result of the test. There were those who thought very strongly you 
shouldn’t give the test to the parent. I just wonder whether that’s a starting point 
for a discussion potentially about differences of views about ethics historically, 
and whether people have had experience of that.
Dennis:  Well, I’ve been retired for seven years now so perhaps I shouldn’t 
comment on the present state, but I would not entirely agree with that because 
my experience was that there was a big consensus among regional genetics 
units about the general approach. Of course, we took part in the Huntington’s 
meetings when all the regions got together and pooled their experience and 
that was very helpful, but I didn’t feel there was a lot of disagreement about the 
basic approach that we should be adopting. I think the big contrast is between 
clinical genetics and the rest of medicine. Any of us who have done genetics 
clinics will be familiar with referrals that come with an assumption that we 
are going to tell this family not to have more children. And we’ll be familiar 
with other clinicians who would say, ‘What do you geneticists do?’ Then, when 
you start explaining they’re clearly thinking, ‘You mean to say you spend all 
your time doing that?’ [Laughter] And how we got into that situation, I think, 
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is linked to the non-medical genetic counsellors coming in and highlighting 
issues, highlighting things that the largely male workforce up to that point just 
took as assumptions without making them explicit. 
Hodgson:  I would develop on that because certainly in cancer genetics, which 
is my main specialty, we find that the genetic counsellors really come into their 
own because most families in the end will make sensible decisions. It is the 
counsellors who are often able to see a person, for instance, who is reticent 
about telling her own BRCA test result to her daughter, possibly because she’s 
feeling guilty, or because she doesn’t know the right time to tell the daughter, or 
feels that the daughter won’t understand, and determine what the reasons are 
beneath behaviour that might appear to others to be intransigent. The genetic 
counsellor is much more able to dissect out people’s fears and motivations 
regarding the communication of their test results to other members of their 
family, and perhaps allow people to come to a more open decision that will 
benefit the other family members than they would otherwise have done if they 
had just been talking to the busy doctor.78 
Clarke:  What Shirley was just saying reminds me that there’s a nice but very 
intermittent and occasional strand of other disciplines coming out with really 
helpful insights into family communication. I’m just reminded of a paper from 
the late 1970s about polycystic kidney disease and about, basically, family cycles 
of mis- or non-communication, that are self-perpetuating, so you find out about 
something in the family in a very distressing and difficult way.79 You therefore 
clam up about it, don’t tell your children, and the same thing happens to the 
next generation too. So, looking at other medical specialties, I agree there are 
a lot of problem areas, but there are some really nice beacons of good practice 
and insight.
Lucassen:  Nina, you did a study looking at communication by men of BRCA1 
and BRCA2 results in families, didn’t you?80 I don’t know if you want to say 
anything about that?
78  Professor Peter Harper discusses the professional specialty of the genetic counsellor in his textbook, 
Practical Genetic Counselling, Harper (1981, seventh edition 2010), subsequently revised by Professor Angus 
Clarke; see Clarke (2015). 
79  Manjoney and McKegney (1978–1979). 
80  Hallowell et al. (2005). 
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Hallowell:  Yes, I would agree with what Angus has just said actually. A lot of 
the family work, not just my own but lots of work in Cardiff, suggests that 
there are definite familial patterns of communication about health and other 
issues. I agree there can be lots of people who can actually add to this, lots of 
communication studies. People have done some very good work, particularly 
the group in Cardiff.81 
Pembrey:  Just coming back to Mike Parker’s point about disagreement between 
clinical geneticists; it’s relevant, only just, to his point, and that is this question 
of having a group discussion around the patients that one is going to see in the 
clinic. This was the importance of being able to have a big enough group that 
involved genetic counsellors and so forth to discuss these issues, which I think 
is very important because you start off with perhaps a difference of opinions, 
but in the end you’ve got to come to some sort of consensus about what you are 
going to say in the clinic. This was particularly brought home to me when I was 
helping, with others, to do some training in Portugal when they were setting 
up their service there.82 In the end there were five clinicians and five laboratory 
people trained, and almost towards the end they said, ‘Right, we’ll be able to 
have five centres?’ And I said, ‘No, no, you can’t possibly have five centres, you 
at least have to have two clinical geneticists in the same centre. You can’t, in my 
view anyway, handle this unless you’ve got somebody also trained to talk about 
it.’ So I think the structure of the way clinical genetics has developed with, 
generally, pre-clinic discussions with each of the patients, which is not that 
common in other parts of medicine, helps to resolve some of these differences. 
Lucassen:  I would echo what Mike says. A lot of people talking about ethical 
issues in their clinical practice want to know what the set of rules is that they 
should use to resolve the issues. If they use different rules they might initially 
at least think, ‘Actually, you can’t do that, you’ve got to think of the patient in 
front of you’, or ‘you’ve got to think of the wider family’. And I think you’re 
absolutely right, that could result in apparent disagreement, but if you talk that 
81  Dr Nina Hallowell wrote, ‘Srikant Sarangi’s group: This group was working as part of Cesagen’s work 
package. Cesagen was the genomics centre that was based at Cardiff and Lancaster universities and was part 
of the ESRC funded genomics network. This network was set up to undertake social science and socio-
ethical research in genomics.’ Note on draft transcript, 6 December 2014. 
82  Professor Amandio Tavares from the University of Oporto invited Professor Pembrey to assist with 
training for the MSc in Medical and Human Genetics from 1985 to 1987. Professor George Anders was 
involved, but mainly Charles Buys (1942–2014), who was Professor of Human Genetics, University of 
Groningen, Netherlands. Note on draft transcript from Professor Marcus Pembrey, 27 August 2015. 
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through then eventually you’ll probably end up agreeing much more than at 
your starting point. Certainly, the stories we hear in Genethics seem to disagree 
with how things should be managed at first even if more common ground is 
found later. I think that’s what you were hinting at. 
Clarke:  I’m really interested actually in the persistence of that dispute about the 
one-in-four risk for people in Huntington’s families. Clearly there are centres 
that don’t practise the way I do. 
Lucassen:  Shocking. [Laughs] 
Clarke:  Quite, clearly [laughs]. That’s despite the best of intentions and a lot of 
discussion, and Nick might be pleased to know that the Huntington’s disease 
forum – the UK Predictive Testing Consortium – carries on and still functions 
because, you know, it’s not running out of things to say – a bit like the Genethics 
Club; there are still lots of things to say. 
Richards:  Could I just make an observation, which is simply the growth in 
numbers of people on the ground. In the days when we first got involved, it was 
more or less the case that we knew, face-to-face, people in every genetic centre 
in Britain, and they came together and they talked with each other. I don’t 
know what the rate of increase has been but when I first knew anything about 
clinical genetics in Cambridge there was one part-time person who lived in a 
Portakabin.83 There’s now a tower block. This really goes back to Mike’s point 
that there is now a large group of people doing the same thing; presumably that 
does lead to consequences and different styles of practice developing and so on, 
in a way that just didn’t seem to be happening in the beginning. 
Parker:  Yes, I do want to pick up the point. I used that example as an illustration, 
but I think it’s the fact that we’ve heard about this long history of thinking about 
ethics, and we’re here today, and I think it’s more, it seems to me that it’s got to 
be more than simply that these are sensitive topics or that they are difficult to 
talk about, or that these are politically troubling. Ethics, if it’s anything, or at 
least a certain important element of it, has got to be about the fact that these 
are problems or situations in which there are different, potentially conflicting, 
ways of answering the question. It’s not just about who should answer the 
question; I think it’s partly about that. It seems to me the story we’ve just heard 
83  Dr Nina Hallowell commented, ‘For example, in cancer genetics there was the cancer genetics group, 
an informal group of people doing clinical, molecular and psychosocial work in cancer genetics, now I 
think this is a formal grouping within the BSGM (British Society for Genetic Medicine).’ Note on draft 
transcript, 6 December 2014. 
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is, at least in part, a struggle about how are we going to resolve some of these, 
not necessarily conflicts between individuals, but certainly tensions between 
different considerations and concerns. We heard at the very beginning from 
Peter about some of the virtues, the character of some of the people working in 
the field and their struggle with these difficult situations. Partly they’re struggling 
because there are different things that are important to them that are pulling in 
different directions. That’s what I was trying to get us to say something about 
really, rather than actually say anything very specific about… 
Lucassen:  Disagreements, yes.
Parker:  I think we’ve heard enough about that, but I do think that’s important 
and enduring.
Farsides:  I wonder, Martin, if you think the interest that social science started 
taking in the matter is also helpful in identifying new potential harms, or a 
different sort of moral consideration, for example, something like stigma, which 
really is an issue in sickle cell disease, particularly. So there’s something about 
the cross-disciplinary interest in genetics that then feeds into the growth of the 
list of the morally sensitive issues to consider. 
Hallowell:  I’ll answer for Martin Richards because I’ve been doing that for 20 
years now [laughter].84 The answer is, yes, he would think that, wouldn’t you, 
Martin?
Richards:  Yes.
Hallowell:  I just wanted to add something to what Angus was saying, a very 
quick comment, and we’ll talk about it later, which is the addition of the genetic 
counselling people, because actually the genetic counsellors have changed, and 
the profession of genetic counsellors has actually changed this field in a huge 
way. Also, I think the genetic counselling profession is very much focused on 
ethics and non-directiveness, obviously, but on ethical practice and that is 
actually at the core of the profession and quite a lot of their education is based 
on that. 
Hodgson:  Just a quick word on the genetic counsellors, although we’re going 
to talk about them later. It was interesting when I did a survey of the cancer 
genetics services in different parts of Europe; an awful lot of them didn’t have 
84  See biography on page 86.   
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genetic counsellors or didn’t give them any responsibility, and having them 
as part of a team has made cancer genetics services more deliverable in direct 
relation to the presence and acceptability of genetic counsellors.85
Harper:  Anneke, I was just going to mention one thing, which is down on the 
programme. Nobody’s touched on it yet and this is this question of how unique 
most of these ethical issues are to clinical or medical genetics, or how much 
are they universal? I’ve seen in the past that this caused a few dust-ups, mainly 
people saying, ‘Oh, this genetics is nothing very different from everything else.’ 
For what it’s worth, my feeling, based on what I’ve encountered over quite a long 
time, is that indeed most of the difficult issues that give rise to ethical problems 
are not unique to medical genetics, but they are certainly an awful lot more 
prominent. Very often they’ve been lurking there in other fields of medicine 
under the surface, or at least unrecognized by the people involved, or maybe 
they have then started to emerge. So half of the value of all the work that’s gone 
on in the genetics field has, I think, been to alert other people to the fact that, 
no, these ethical problems aren’t absolutely unique, but we seem to meet the 
sharp end of them. I think, as geneticists, we’ve done a fairly reasonable job at 
exposing these issues and arguing about them in a way that has been unusual 
in other medical specialties.86 This rather leads on to the challenges for others. 
Well, if these issues aren’t particularly unique and you begin to identify them, 
how are you going to cope with them? I think that’s certainly become true in the 
cancer field, but also in the neuroscience field. There’s a sort of neuroethics that 
has come along in the wake of ethics in genetic issues.87 I don’t know what other 
people feel, but my feeling is really the issues aren’t that unique, but maybe the 
degree and complexity to which they affect practice are, if not unique, certainly 
kind of unusual.
Turnpenny:  We face the situation in cross-talk with our colleagues and with 
managers especially; the whole healthcare system is geared up to the individual, 
largely, to the person with a symptom who comes and needs to be assessed 
85  Hodgson et al. (1999). 
86  ‘…the field [of medical genetics] attracted medical doctors whose background in general medicine and 
paediatrics had made them aware of the difficult, often tragic, problems faced by families with serious 
genetics disorders and more able to relate to families in discussing these problems. Having the time to do 
this through the necessary steps of taking a pedigree and going through the various risks and options was 
an important factor, one largely lost in more pressured medical specialties’, quoted from Harper (2008), 
page 456. 
87  Illes and Sahakian (2011). 
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and investigated and treated and so on. I think we’re always in those sorts of 
discussions pointing out that the true patient in the genetics clinic is the family, 
not only the individual. This we, of course, know, but we see that it’s quite 
difficult for others to fully, fully appreciate what the implications of that are. 
It affects how we document what we do, it affects the type of notes we have 
because we have family files, which contain details about many individuals, 
not just one individual. It determines how we talk about families rather than 
individuals. It has a big effect on the way we investigate people with genetic 
testing, of course. I think that’s one of the key points in the transition, or at least 
to understand the unique place of ethical issues in genetics, is the place of the 
family as opposed to the individual. It’s still an issue communicating that and 
helping people to understand it.
Fryer:  I remember doing one of your clinics, Peter (Harper) in Swansea, and 
being faced with the issue of a child who had a parent with adult polycystic kidney 
disease, and the issue was that of testing the child by doing an ultrasound. It 
was not long after I’d started working for you, and I’d come from a paediatric 
background, and in paediatrics my experience was if the parents requested it, 
you just did it. Then I came back to Cardiff and we were talking about this 
issue. Marcus was talking about pre-clinic discussions; we had a lot of post-clinic 
discussions in Cardiff as well at Thursday lunchtimes, I remember well. And the 
discussion presented the question : ‘Well, is this the right thing to do?’ Obviously, 
we were then very influenced by your experience in Huntington’s and so on. So 
I think Peter’s point is very, very well made; the issues may not be different but 
they were crystallized in genetics, in this case the particular issue of genetic testing 
in children.88 This issue was crystallized in clinical genetics practice and then that 
brought it to the attention of paediatricians and others dealing with children that, 
to be honest, having been a paediatrician, I hadn’t really thought through.
Lucassen:  Yes, polycystic kidney screening in children is a perfect example, isn’t 
it, of that bridge between paediatrics and clinical genetics.89 Angus, I don’t know 
if you want to say something about the history of genetic testing in children? 
Clarke:  Well, I was going to say something to come back to Peter Turnpenny’s 
remark actually about the family being the patient, and to tie that in with 
88  See Clarke (1997c). 
89  Professor Anneke Lucassen wrote, ‘In that a kidney scan in a child might reveal an inherited tendency to 
adult disease.’ Note on draft transcript, 16 October 2015. 
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what Bernadette mentioned about surveys, international surveys – I think you 
mentioned, didn’t you, Dorothy Wertz and Kåre Berg and Fletcher, yes90 – 
because, of course, families take different shapes in different communities and 
societies, so you get systematic differences in practice and attitudes to things 
like non-directiveness and everything else in different parts of the world. That’s 
a whole issue that we probably aren’t going to get on to, and explore, but it’s 
worth flagging up the fact that a lot of people who have trained in one place, 
say North America or Europe, then go and practise in other parts of the world. 
This means that you’ve got professionals who are socialized into one approach 
to dealing with families then trying to train their colleagues and work with 
families who are expecting something different; it still creates lots of conflicts 
and tensions. 
Lucassen:  Do you also want to say something about genetic testing of children? 
Clarke:  I suppose that emerged out of the predictive testing for Huntington’s 
work really. I think David Craufurd talked about it, and then Peter Harper 
and I wrote a paper, and then there was the Clinical Genetics Society working 
party.91 There have been several working parties since then so the practice has 
changed slightly, and I think the principle is laid down of trying to preserve 
the autonomy of the child for a future where that isn’t going to put them 
at a disadvantage medically or in some other way.92 That principle is still 
current. It takes slightly different shapes in Europe maybe from how it does in 
the UK. 
Lucassen:  I think that as a principle that can take a bit of time to communicate, 
so I think, despite all those guidelines, we still get parents saying, ‘I want my 
child tested’, but then, when you talk to them about the possible disadvantages 
of testing they get to an understanding of the reasons for possibly delaying 
testing that they don’t have when they first come in to ask for it. That hasn’t 
really changed over the years, but what has changed is the technology or the 
ability to test, so it’s easier to get the test done without that discussion, I suppose, 
so I agree with you, the principle is interesting.
90  See page 21, and Wertz and Fletcher (1993). 
91  Dr David Craufurd founded the first multidisciplinary management clinics for Huntington’s disease 
in the UK; www.manchester.ac.uk/research/david.craufurd/research (accessed 5 November 2015); see, for 
example, Tyler, Ball, and Craufurd (1992). Harper and Clarke (1990).
92  Borry et al. (2009), and European Society of Human Genetics (2009). See also Clarke (1994). 
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Clarke:  Yes, there’s probably less weight put on carrier testing now than there 
was, I suppose the same with newborn screening for sickle cell, at least in 
England, in identifying all the sickle cell carrier infants.93 Then, obviously, that 
was a completely clear conflict between the genetics professional guidelines 
and the newborn screening practice as it came in, so that caused a degree of 
unhappiness. That was quite an interesting clash of ethics. Well, in Wales we 
don’t identify haemoglobin, sickle globin carriers, because we use a slightly 
different technology that deliberately doesn’t generate that information. But in 
England the sickle carriers are all identified. So, in terms of notifying families of 
results the vast majority of results are carrier results not affected results, which 
raises workload questions and all sorts of things.
Modell:  Yes, and whether one is treating families or individual patients. 
Lucassen:  But also, a little bit about whether one is setting out to test or 
whether one has found it as a result of looking for something else. That’s another 
difference, isn’t it? So if you find carriers as a result of looking for affected 
children that’s different to testing specifically for carrier status.
Modell:  Yes, but then you’re making a choice about whether you’re case finding 
or whether you’re a geneticist looking for families who may benefit from genetic 
information.
Lucassen:  Absolutely. No, I think the only point I was making is that there is 
a difference between setting out to look for something and finding it as a by-
product of the test. 
Dr Mark Bale:  It’s just an interesting reflection; I’m relatively new to all 
of this, and I’m finding it fascinating to see what we can do with some of 
our horizon scanning. Even though I’m relatively new, I’m still one of the 
people with the longest experience of clinical genetics in the Department of 
Health (DoH). I got involved in genetics generally in, I suppose, the mid-
1990s. In the Department, people come to me assuming that we’ve got the 
ready-made solutions to, say, what do we do about CJD (Creutzfeldt–Jakob 
disease) testing, or what do we do about Alzheimer’s testing is now coming up, 
that they are going to be able to pick up and take off the shelf a kind of model 
that works for genetics.94 
93  Sickle cell disease screening for newborns was introduced in England between 2003 and 2006; see 
Streetly, Latinovic, and Henthorn (2010). 
94  See for example, Bechtel and Geschwind (2013). 
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I think it is coming back to what you said; it does seem that genetics has had to 
take these steps and work on practical issues that now other people are coming 
into. What tends to happen when they talk to me about what their system is for 
genetics is they go away scratching their heads, ‘How on earth are we going to do 
this in practice?’, and it still happens in screening. Screening people assumes that 
we will be able to give them a solution on things around carrier testing, how that’s 
going to be recorded and transmitted to families, and we tend to say to them, 
‘Well, I thought that was your area?’ [Laughter] It’s quite an interesting one 
because it just reminds me actually that genetic testing has been in the vanguard 
for quite a lot of this, and we should learn some useful lessons from that.
Harper:  A very quick point while we’re on the screening area; it’s something I 
just made a note of on the train coming up. One of the reasons why, probably 
quite numerous reasons why, geneticists and other clinicians such as obstetricians 
often have very different views about screening, particularly antenatal and 
generally reproductive screening, is that geneticists have been brought up in a 
Bayesian world.95 On the whole, most of their practice is with high risk families, 
but they are used to the concept that the person who is at high risk, and worried 
95  ‘Bayesian analysis is commonly used to calculate genetic risks in complex pedigrees, and to calculate the 
probability of having or lacking a disease-causing mutation after a negative test result is obtained’; quoted 
from Ogino and Wilson (2004), page 1. 
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and comes to see you, is utterly different from the person out there in the 
population who usually is unaware of the problem, maybe doesn’t want to know 
about a problem, etc. For geneticists, it’s always been one of the tenets; these are 
different situations, radically, and you have to handle them differently, whereas 
for many others, and I think quite a few epidemiologists and public health 
people are included in this, it’s all lumped together and we’re feeling a bit, that 
what’s good in a high-risk situation, if you can do it technologically then you 
should be able to apply it in a screening situation. Of course, you can’t always 
do that. So, although it’s nothing to do with ethics, it actually does underpin 
quite a few of the ethical differences and dilemmas which occur, especially in 
the screening field.
Lucassen:  Before the break we were talking about genetic counsellors and how 
they’ve influenced both the profession in general and the consideration of ethical 
issues. One thing, of course, to note is that there are no genetic counsellors 
here today.96 That’s not for want of trying, but unfortunately none whom we 
approached were available today. From a personal perspective, one of the biggest 
changes I’ve seen in clinical genetics is to do with genetic counsellors. When I 
started in clinical genetics, I always had a genetic counsellor in clinic with me, 
and co-counselling was a valuable and valued part of the clinical approach. 
Recent financial cutbacks to NHS (National Health Service) genetic services, 
and in the face of increased referral rates and thus waiting times, means that 
we now have to see patients separately.97 In fact, the last time I had a genetic 
counsellor with me was probably about a year ago, and that’s a loss to the service 
I can provide. It makes a huge difference to clinical practice: if you’ve got two 
people in a room, and a genetic counsellor is there to co-counsel with you and 
pick up the cues you don’t pick up yourself, that’s incredibly helpful for the 
overall delivery of genetic services. I think it’s a huge loss that we don’t have that 
anymore. But I wondered if we could use that starting point to go back and say 
96  The development of genetic counselling was discussed at a previous Witness Seminar to which the 
counsellors Mrs Lauren Kerzin-Storrar and Professor Heather Skirton contributed; see their comments 
and biographies in Harper, Reynolds, and Tansey (eds) (2010); pages 68–73, 124, 129. See also McCarthy 
Veach, LeRoy, and Bartels (2003), Chapter 2, Overview of genetic counseling: history of the profession and 
methods of practice, pages 23–37; and Harper (2010), pages 4–5. See also note 110. 
97  Professor Anneke Lucassen wrote, ‘These [cutbacks] were gradual, but I noticed the effect on counselling 
around 2012/2013, and were perhaps more to do with increased referral rates with static funding, but at 
local NHS Trust levels there are often year on year cutbacks of five to ten per cent. In larger specialities these 
can often be absorbed but in small specialities like genetics this means fewer staff for the same or increasing 
patient referral rates.’ Email to Ms Emma Jones, 21 September 2015. 
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a little bit about genetic counsellors coming into the profession? Angus, given 
that you’re in charge of the training programme for genetic counsellors, I don’t 
know whether you want to represent genetic counsellors today?
Clarke:  I certainly couldn’t do that, I wouldn’t be allowed to. I can reflect just 
a little bit upon their changing nature. They were initially called co-workers, 
associates, and I know there was a pool of people in that role when I started 
in Cardiff ’s genetics service in the 1980s, which consisted of a social worker, a 
psychologist, a science graduate, a couple of nurses, and a slightly fluctuating 
body of a few more who shared an office and would always have words of 
wisdom and a lot of experience coming from very different areas. I found that a 
very good model, of having people from many different backgrounds working 
together. Then, what happened is there was a bit of professionalization of genetic 
counselling, and it became very nurse dominated for a bit, and to me that was 
less interesting, the fact they came from a very uniform background. I think 
the role of nurses is really valuable in that group, but I think when it looked 
like it was becoming almost totally nurse dominated, I felt it lacked something. 
Now, both Manchester and Cardiff have courses for genetic counsellors, so 
we’ve got to a predominantly non-nurse body of genetic counsellors.98 There 
are a few nurses and other healthcare professionals in there, but I think nothing 
like enough now. I guess these things come in cycles, and we’ll have to work 
out a way to make it easier for healthcare professionals, established healthcare 
professionals, to move through some sort of training into the genetic counsellor 
role.99 
Lucassen:  The general idea that the genetic counsellor adds to the genetic 
advice or genetic information that the clinical geneticist gives is something that 
is worth picking up a bit more because, as I said, historically that’s fluctuated 
quite a bit, hasn’t it? 
Hodgson:  There are two issues here. I think genetic counsellors certainly add 
a great deal to the genetic counselling clinic’s agenda because they come to 
the clinic with a different background. To go back to my survey, it was quite 
interesting that in Germany, for instance, there was a lot of antagonism to the 
98  MSc programmes in genetic counselling are available at the University of Manchester; see 
www.mhs.manchester.ac.uk/postgraduate/programmes/taughtmasters/geneticcounselling/, and Cardiff University, 
where the course was founded by Professor Angus Clarke; see http://medicine.cf.ac.uk/cancer-genetics/research/
medical-genetics/our-teaching-and-training/msc-genetic-counselling/ (websites accessed 25 June 2015). 
99  See, for example, Skirton et al. (1998).
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idea of having genetic counsellors, who were not doctors, doing any serious 
counselling.100 They’ve only just started taking on a few counsellors to share some 
of the clinical responsibility of genetics clinics, particularly cancer genetics. But 
the other thing is that, actually, genetic counsellors can do a lot of the cancer 
genetics without doctors, so long as they work as a team. So they’ve found a 
role that perhaps they didn’t used to have, but they have a lot of training that 
I certainly didn’t get in terms of picking up cues about family emotions and 
relationships, and they have a very important role.
Lucassen:  One of our other headings is the involvement of social scientists in in 
clinical genetics services (see Table 1). 
Hallowell:  I just wanted to pick up on this issue around the genetic counsellors 
and what I said earlier. I have been the external examiner at Manchester, and 
I’m currently the external examiner at Cardiff for the MSc courses, so these 
are the two courses in the UK where genetic counsellors are trained. It seems 
to me that what is absolutely fundamental to these courses is this idea around 
ethical issues, at every single level. That’s particularly clear when you come to 
look at the student dissertations, which are always about what I would call 
possibly ‘lived’ ethical issues rather than your four principles of Beauchamp 
and Childress.101 I think that ethics is actually very integral to that training; I’m 
not suggesting for a minute that the clinicians among you are not ethical, it’s 
just that they focus very much on lived ethical issues: consent, confidentiality, 
autonomy, are all very much woven into their training at every level.
Clarke:  To come back to Shirley’s point about Germany: until very recently 
there were financial reasons why German genetic centres would not want to 
have counsellors, and that’s because they got all their reimbursement by tests 
performed. They were apprehensive that counsellors would talk people out of 
having tests [laughter] so they would undermine their own basis for salary. But 
that has now changed and they can bill for the communication counselling side 
of it. That’s the last few years.
Fryer:  Just going back to the history again. I think that while Shirley’s comment 
about variation across Europe is important, actually, when I came into genetics 
there was quite significant variability across the UK. I trained, as I’ve said before, 
with Peter in Cardiff, and perhaps Peter will say something about this later, 
100  See note 85. 
101  See page 20. 
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as to how that ethos of having the involvement of genetic counsellors came 
about, which, as Angus rightly said, included Audrey Tyler from a social work 
background. Indeed, there were a variety of different disciplines among the 
group in Cardiff. When I came to Liverpool, we had what was called a genetic 
health visitor, and we actually had two genetic health visitors. Although we 
were a very small department, we were built along the same model as Cardiff 
and my closest neighbours in Manchester where they, of course, had quite a 
lot of genetic nurses or whatever they were called at the time and, in addition, 
they had Lauren Kerzin-Storrar as an American who’d come through their 
genetic counselling training programme.102 They became very pro developing 
non-nursing genetic counsellors in Manchester because Lauren made such an 
impact on them. They were very pro the development of individuals coming 
from a genetic science background and then training them as counsellors as part 
of the team alongside nurses. 
Meanwhile, I think there were a lot of other departments across the country 
which did not have any genetic counsellors or other co-workers. From an 
historical point of view, it’s very important to realise that this was built up in a 
very piecemeal way. The role of genetic counsellors in the way you’ve described, 
and what I experienced in Cardiff and then took into my own practice in 
Liverpool is not the way that the role of genetic counsellors has developed in 
other centres – I think that has to be recognized.103
Dennis:  Well, my personal experience may be worth recounting. I’ve mentioned 
that I started with Cedric Carter in Great Ormond Street in 1971/72, and 
the role of Kath Evans there; she was one of a group of three or four people 
who were employed as researchers.104 Cedric had these big studies where he 
followed up families of children who had been through Great Ormond Street 
with various malformations, and so he needed a team of people to go out and 
interview families to find out recurrence risks, and Kath was primarily one of 
those. She was trained as a social worker, but a very helpful addition to the clinic 
it seemed to me. Then, in 1976 I went to Buffalo in New York State for two 
years, and there was a lady called Gillian Ingall who was also a social worker by 
training, or originally she was one of the ones who had been a medical almoner 
102  See note 96. 
103  For a discussion of the profession of genetic counselling and training internationally, see Bowles Biesecker 
and Marteau (1999). 
104  See note 31. 
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but she’d gone to America with her husband who was a surgeon, had taken an 
interest in genetics and got a job.105 And there was Barbara Bernhardt, also from 
a science background there, so they both functioned as non-nursing genetic 
counsellors. Gillian was quite scathing about the people emerging from the 
genetic counselling degree course in North America, because she felt they didn’t 
have the sort of hands-on experience you got if you had a nursing background. 
I came back to Southampton in 1978, and I was trying to think why was I so 
keen to get somebody to support me in the clinic. I think it was just isolation 
because, apart from Elspeth Williamson, [a clinical geneticist], who was part 
time, I felt very much on my own, I felt completely unprotected. I was sitting in 
the clinic trying to do something that I really didn’t feel I was properly trained 
to do, and I just felt it would be so helpful to have someone who could have 
a separate viewpoint on some of the things that I was having to discuss with 
families. So I tried very hard to get somebody, but I tended to think of it as 
someone from a nursing background and in fact when we got the money a few 
years later, we managed to appoint three people all from nursing backgrounds. 
I thought at the time it seemed very helpful to have somebody with a medical 
insight, and hands-on medical ability to sit with and talk to somebody 
sympathetically, but also know what the medical problems were. There weren’t 
the courses, degree courses in genetic counselling hadn’t started up at that point, 
so we were very lucky. I mean we ended up with amazingly bright people from a 
nursing background, which is one very good way of doing it, I would say.
Turnpenny:  I’ve been involved in the Peninsula Clinical Genetics Service for 
21 years now and we had a half-time nurse when I started, and then began to 
appoint some new folks soon after.106 We appointed from nursing, established 
nursing backgrounds, health visitor backgrounds, and it seemed to work very 
well. The one great advantage of such a person was that they had a bedside 
manner, generally speaking, and for somebody who was a health visitor they had 
this great ability to get across the doorstep, as I always used to say. A lot of work 
was done by home visiting at that time, much less now, of course. To win the 
confidence to get into somebody’s home, that was a great asset. I have to admit 
to being a person who was a little bit worried about people coming straight 
off degree or MSc courses with their genetics training but no care training, or 
105  Gillian Ingall was a President of the National Society of Genetic Counselors in the USA, see Heimler 
(1997). 
106  A service for the population of Devon and Cornwall, in the south-west region of the UK; 
see www.peninsula-genetics-service.org/index.html (accessed 25 June 2015). 
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healthcare training as such, and I was worried that they wouldn’t have a bedside 
manner that would actually facilitate their ability to be good counsellors. But 
over the years I’m glad that I’ve been proved wrong in that, because I feel we’ve 
had some absolutely excellent candidates and graduates from those sorts of 
courses who do get a very good training in the counselling side of things. 
The other thing I wanted to say was that there came a time, around 10 to 12 
years ago, when a little bit of friction began to emerge between the medics and 
the counsellors about the counsellors potentially having their own caseload that 
would be independent and never seen by the consultant. It was actually Peter 
Farndon, when he was Chair of the Clinical Genetics Society, who said, ‘We 
need to deal with this. We need to have some sort of working party to look 
at the demarcation of roles, essentially.’ That was a group that I sat on, and 
actually it was pretty straightforward. We were able to work out quite clearly 
where the boundaries were, in fact, and where a genetic counsellor (GC) should 
not go, if you like, and which was territory for the medics. As part of that we did 
look at what was happening in other places in the UK, and in Europe, and the 
service, and the country that is perhaps closest to us is the Netherlands where 
their medics work in a similar way. They have rather a lot of counsellors, but in 
fact their counsellors do far less than our counsellors here and that’s probably 
still the case, although I don’t have an update on that.
Lucassen:  I can give you an update on that. There are roughly about a quarter 
of the number of counsellors in the Netherlands compared with the UK, and 
they don’t have an independent caseload like UK ones do. Medics are ultimately 
responsible for any patient referred, and this has led to a practice where medics 
have to pop their head around the door for any consultation that a GC holds 
because they are nominally responsible. So it’s quite different here. 
Hodgson:  From the point of view of cancer genetics, the ability to deliver cancer 
genetics services did seem to correlate with how genetic counsellors were accepted 
into their role and given more responsibility, but again, it comes back to the 
issue of defining their role very clearly so that people don’t feel threatened that 
somebody is going to impinge on their turf. Also, that they might make mistakes 
because they are dealing with something that they aren’t trained to deal with. 
Lucassen:  Can I just ask: how do you feel then that genetic counsellors have 
impacted on the emergence of an ethical dimension in clinical genetics? I 
suppose that’s what we’re trying to get at really, isn’t it? 
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Harper:  Personally, I’d completely like to go along with what Nick Dennis was 
saying about how isolated one can feel without somebody to discuss things with 
and back one up, especially, I found, in something like Huntington’s where 
stressful situations are abundant. We were also very fortunate in Cardiff to have 
a superb social work-trained person, Audrey Tyler, who was, well, she was just 
magnificent with the families, and she had an academic frame of mind as well.107 
Just to go back right to the beginning, the situation in North America, which 
I didn’t realise but it actually did develop rather differently in terms of genetic 
counsellors. When I was working in North America things hadn’t really 
differentiated, things were at the stage that Angus mentioned; there was a nurse, 
or two of them, and other people, doing rather specific but different areas of 
work, often research-related. There weren’t any defined genetic counsellors. 
Then the course at Sarah Lawrence got underway with the backing of clinical 
geneticists.108 But at some point, and I only realised that very much later because 
I’d missed out on it, I’m very glad I had, a lot of tension had arisen in the North 
American situation, which started off on a funding basis as to who could be 
reimbursed for what, and then what happened, more or less, was the genetic 
counsellors who were starting to emerge got excluded because they couldn’t be 
registered along with medical practitioners. Then the counterpart happened, 
which was when they formed their own society, clinical geneticists were excluded 
very specifically. So there was this polarization, and a lot of resentment, which I 
think has more or less diffused now. Fortunately, perhaps not absolutely entirely 
but very largely, we missed out on that in this country, because I think now 
everybody would realise that there are two complementary, and indeed equally 
valuable, roles and I’m just very glad we didn’t have that period of bitterness. 
Then, right at the very beginning, of course, we mustn’t forget that the people 
doing genetic counselling were non-medical biologists, and actually one of the 
best books is by Sheldon Reed called Counseling in Medical Genetics, written 
in the 1950s.109 He was a Drosophila geneticist, who, after the war, took a post 
in what was a sort of eugenic set-up, but he basically completely ignored this. 
He says so in his book. He was clearly, even though he had no training on the 
ethical and social aspects, he was clearly a very empathic person. There was a 
107  See, for example, Tyler and Harper (1983). 
108  Sarah Lawrence College, New York, offered the first postgraduate course in genetic counselling in the 
USA; see www.sarahlawrence.edu/genetic-counseling/ (accessed 6 October 2015). 
109  Reed (1955). 
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good study recently on him in a book by a person called Minna Stern, it’s called 
Telling Genes: The story of genetic counseling in America.110 
Modell:  I would like to raise the question of who does genetic counselling 
because, as genetic knowledge expands, more and more clinicians really are in 
a situation where they need to provide genetic information. I’m aware of a 
couple of studies that were focusing on the transmission of genetic information 
in British Pakistani families. One was in Blackburn and one was in Bradford, 
where the researcher visited families with known genetic diagnoses for which 
the DNA basis was known and carrier testing was feasible, and asked where they 
got their information from.111 It turned out that a minority of these families, 
both in Blackburn and in Bradford, had actually seen a genetic counsellor. 
Where they had their information was from the paediatrician. Now this was a 
particular ethnic group. Why hadn’t they seen a genetic counsellor? Had they 
been offered? Had they not gone? Had they forgotten? I don’t know. As far as 
they were concerned, the person who provided them with genetic information 
was the paediatrician. And that, when you consider what’s required, the timing 
that’s required and so forth, the skills, you do feel that community paediatricians 
really need a new group of community genetic counsellors who can work with 
them, the community and clinical geneticists. So when we’re talking about 
genetic counselling, you were talking about the development of the profession, 
but I think there’s a huge unmet need. 
Lucassen:  I think it’s a very good question, as well as ‘what is it that makes 
someone a genetic counsellor?’ We’ve described genetic counselling in the 
context of clinical genetics, haven’t we, and you’re quite right that the demand 
for genetic counselling also happens outside the profession. 
Modell:  But it’s getting, it should be getting more and more recognized that 
every clinician needs to have basic genetic counselling skills.112
Lucassen:  It’s also still not uncommon for a patient to ring up and say, ‘I’ll have 
the genetics bit but not the counselling, thank you.’ So the term counselling 
also has very different interpretations, doesn’t it?
Hallowell:  I just wanted to make an observation, which is three of you at least 
have said that you find it very lonely doing genetics consultations, and I wondered 
110  Minna Stern (2012). 
111  Ahmed, Green, and Hewison (2002). 
112  See, for example, Emery and Hayflick (2001). 
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whether that is because there is something specifically difficult ethically about 
genetics, coming back to the question about genetic exceptionalism before. 
Why do you all feel so lonely when you’re doing the consultations?
Dennis:  I think it comes down to having not had any training in how to talk 
to people really. You’re giving people bad news, and it took me many years to 
have some inkling of the best way of doing that. I was self-taught really, and I 
think by the time I retired I wasn’t too bad at it but the first half of my career 
I was pretty bad at it. I would arrive at a point in the consultation where I’d 
think, ‘What the hell am I supposed to say next?’ I just wish I’d had somebody 
else there who could have looked over my shoulder and made some suggestions. 
Hallowell:  Lots of other specialties give bad news, so is there something special 
about genetics? Is it because there are especially difficult ethical issues?
Dennis:  I think it’s just because I qualified in 1968, and most of the people 
around now qualified later than that.
Lucassen:  But there would be oncologists who qualified in 1968; would they 
also describe this loneliness? I think Nina’s point is well made. What is it about 
that situation that I recognize, but I can’t quite put my finger on what it is? 
Dennis:  The nature of what you’re saying in genetics is different from what 
might happen to you because of this illness. I mean you’ve come because you’ve 
got an illness, so we all acknowledge that you’ve got an illness. So that’s the 
difference from when ‘well’ people are coming to you and perhaps getting 
information about what might happen in the future, or what might happen 
to their children. It’s a different order of knowledge really. I think that does 
make it harder. You’re presenting them with a situation that perhaps they hadn’t 
thought about before. They don’t know how to react to it and it’s quite difficult 
sometimes to think how you ought to, well to think how you can, help them. 
Hallowell:  Martin, we’ll do it together: Is it the ethical thing or is it a family 
thing? 
Richards:  Carry on. 
Hallowell:  I was just trying to get at if it is any different from any other area 
of medicine, and is that because it’s an ethical difference or is it just a technical 
difference maybe, because it’s certainly not a technical difference. Do you think 
there are special ethical issues, really, within genetics?
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Pembrey:  I’m not directly going to answer that question, but the first thing to 
say is that in all my practice – I stopped clinical practice at the end of 1998 – 
we never in discussion referred to Beauchamp and Childress’ four principles, 
we never used the word ethics particularly. What we were worried about was 
delivering our professional duty of care, and in other parts of medicine the 
professional duty of care focused largely on the individual was much better 
defined than with clinical genetics initially. We were feeling our way, particularly 
in the 1970s and 1980s. And just to talk about giving bad news, in 1966 when I 
was a house officer, I told a patient who was having a biopsy for what might be 
Hodgkin disease, I think, I promised that I would tell her the result when she 
came back from the operation. My consultant was horrified. He said, ‘You can’t 
just take it upon yourself to do that, but if you’ve promised…’ I said, ‘Well, I’ll 
deal with it’, and he said, ‘Well, I’ve seen the hope drain out of their faces when 
you give them that news’. That would seem amazing now, but in developing 
the clinical practice in clinical genetics we basically just hung on: ‘What is our 
professional duty of care? How are we going to help not just this couple who are 
coming, or this person, but the family in general?’
Lucassen:  The lived ethics that Nina was talking about. 
Pembrey:  Maybe that’s what the academics call it but we didn’t call it that.
Lucassen:  No.
Pembrey:  We were very definitely engaged in protecting what we had built 
up for these families at high risk. In 1987, for example, when there was a 
parliamentary debate on MP David Alton’s Bill on whether the legal age of 
termination of pregnancy should come down to 18 weeks, and what that would 
mean for these families; Bernadette (Modell) and I were travelling back from 
a meeting in Cardiff – that would have been in 1985, 1987, perhaps 1986, 
something like that – and anyway, it was a meeting in Cardiff. Leading up 
to this parliamentary debate, the pro-life lobby, the anti-abortionists, had a 
phrase, a catchphrase, ‘search and destroy’; that is, all that prenatal diagnosis 
and counselling is search and destroy. We had to work out a phrase, and we 
decided what it was by the end of the train journey: what did we deliver? 
We ‘restored reproductive confidence’. That phrase came out of the work 
that Bernadette had done on thalassaemia, showing in the Greek Cypriots 
of northern London that if they didn’t know anything at all, if they just had 
children, and lots of them, with Mendelian ratios, some of them would have 
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the disease and die.113 If they were given genetic counselling but nothing else, 
they were too frightened to have children. They stopped having children, 
73 per cent,114 and so what we were doing by introducing prenatal diagnosis was 
restoring reproductive confidence; so all that went on. 
We were dealing with issues that were there at the time in a practical way, 
worrying about professional duty of care. With all due respect, I went on a 
Raanan Gillon course on ethics and philosophy for medics, and so on, and they 
had a variety of medics.115 When I arrived there they said, ‘Oh thank God we’ve 
got a medical geneticist, a clinical geneticist, with some real examples of ethical 
issues’. They were desperate for practical examples, you know. So they were 
interested, and they called it ‘ethical issues’ but we didn’t use the phrase. Maybe 
I’m out on a limb on this one.
Lucassen:  But does that matter that you didn’t call it ethical issues? You’re 
describing ethical issues, does it matter that you didn’t call them that?
Pembrey:  No, no, it doesn’t matter at all but we developed things on the hoof a 
bit, to be honest, with the professional duty of care being the thing, principally, 
that we talked about.
Modell:  And listening to your patients. I was thinking that the way the ethical 
approaches to new technical developments happened was when you informed 
your patients about them, you listened to their reactions and those were so 
deeply educational that they then led on, I think, in most practising clinicians, 
to a certain type of ethical practice, very non-directive basically. Then it was 
an empirical collection of the attitudes of those clinicians that led on to the 
defining of fundamental principles of genetics.116 But the bottom line is the 
patient, the consultation, the patient interaction, and being influenced, being 
open to what the patient said. 
I’d like to just add one final thing about loneliness. I did understand when 
you were talking, I realised what you were talking about because there was a 
breakthrough moment for me at the time that I was involved with the patients 
113  Modell and Berdoukas (1984); see Chapter 4, ‘Thalassaemia in Britain’, pages 76–85. See also Professor 
Bernadette Modell’s account of this work at a previous Witness Seminar, Jones and Tansey (eds) (2014). 
114  Modell, Ward, and Fairweather (1980). 
115  See note 46. 
116  See Professor Bernadette Modell’s comments on page 21. 
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in founding the UK Thalassaemia Society Support Association and we had 
some meetings that were quite emotional.117 In one of those meetings I suddenly 
realised and said, ‘I understand now. You don’t, you’re not expecting me to solve 
your problem, you just want me to be there for you?’ and they said, ‘Yes’. That 
was a great relief, and I certainly didn’t feel lonely after that. Does that address 
part of what you were saying about loneliness?
Dennis:  Yes, that is part of it, it’s the feeling that you want to make everything 
right, and you can’t. But I think the main source of difficulty for me was not that 
there were ethical problems involved in some of these consultations, because I 
think that’s not the most difficult part of it. I think it’s the fact that they didn’t 
know what they were coming for quite often. They were not ill and you were 
telling them something that was in a mental space that they perhaps didn’t even 
know existed, and so I think that added to their difficulties and their distress. 
As a doctor, I did want to make that right, and I couldn’t see how to make that 
right. I didn’t have time to get on the phone the next day, or go and visit them 
at home or anything like that, but I had this idea that there might be somebody 
who might be able to do that. 
Modell:  Yes, and that comes back to what Peter was saying about the origin of 
working in medical genetics when there wasn’t much you could do, and you 
wondered why were people so welcoming and so pleased to see you. Because 
you were there for them.
Parker:  I was just going to respond to Marcus’ point from the other perspective, 
from the other side, from the philosophy side in a way, about the involvement of 
humanities and social sciences. In the second half of the 1980s I was doing my 
PhD and I was living in London, and I was running, with Don Hill, a seminar 
series for the Society for Applied Philosophy, so workshops essentially on a 
Saturday morning, and anyone who wanted to could come.118 I remember there 
were several of those over the years that had something to do with genetics in 
them, and I remember sessions led by various people. But if I’m really honest, 
they were often wonderful speakers and I loved their work, but the issues didn’t 
grab me; I didn’t find them that interesting. But something happened later on, a 
couple of things happened, which changed it for me. In 1998 I had a fellowship 
in Melbourne, and I did a bit of work with Bob Williamson at the Murdoch 
117  For the UK Thalassaemia Society, see http://ukts.org/about-the-ukts.html (accessed 30 June 2015). 
118  For Don Hill, see, for example, Almond and Hill (eds) (1991). 
Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research
60
Institute, so I spent some time there.119 I was asked to facilitate a meeting of 
genetic counsellors and geneticists, and there were some interesting cases. Then 
the second thing was, when I moved to Oxford in 1999, I met Anneke and this 
was on a one-week medical ethics workshop where clinicians brought cases or 
issues, things they wanted to turn into papers. I remember Anneke brought a case 
about non-paternity. Both of those struck a real chord for me because the thing 
I’d found uninteresting about analytic philosophy and its approach to ethics was 
that it didn’t touch on the things that I thought were really important in ethics, 
so the lived experience of people struggling with how to live and how to make 
difficult moral decisions is what really grabbed me, and there was none of that in 
these fairly abstract philosophical talks. Those two experiences, being in a genetics 
clinic in Melbourne and working with you, Anneke, on that paper around this 
difficult decision, really made ethics much richer for me and made it much 
more interesting and engaging. At that point for me, personally, obviously other 
people’s stories will be different, I was always socially minded as a philosopher, 
both politically and theoretically, but those two things came together, and the 
prism through which I saw philosophy ignited in a really interesting way. 
Lucassen:  I think that’s really interesting because I think what I’ve been hearing 
is that ethics is conceived of in different ways and some people talk about formal 
ethics or lived ethics. For me, it’s just an echo of what you’re saying, is that I 
didn’t really know how to apply formal ethics or frameworks, or whatever, in my 
clinical practice. I couched ethics as good professional practice. But somehow 
meeting Mike and talking through things in meetings with him, in a lived way, 
made ethics in practice seem very different. 
Parker:  Yes, I think there’s a lot in common. I think it’s very important; I 
mean the term ‘formal’ is quite problematic there I think because it suggests, 
without explicitly saying it, that there are other ways you can think carefully, 
systematically, and thoroughly about moral problems and engage with them, 
not just thinking obviously. There’s a whole range of things going on, so I 
wouldn’t want to suggest what we’re talking about is ‘informal’; I think there’s a 
discipline to it, and it’s real and engaged and rich. It’s not formal in a sense that 
I don’t think even Beauchamp and Childress really saw it as either, but it’s the 
way they tend to be interpreted.120 So to say ethics is not formal doesn’t mean it’s 
not serious or engaged, I don’t think.
119  Professor Bob Williamson was Director of the Murdoch Institute and Professor of Medical Genetics at 
the University of Melbourne (1995–2004). 
120  Beauchamp and Childress (1979).
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Lucassen:  No, that’s a very good point. 
Mumford:  I want to add something, also in response to Marcus, and to introduce 
another dimension. In 1990 I was asked to be the secretary of a new ethics 
committee that would be examining the issues arising in the ‘Children of the 
Nineties’, or ALSPAC (Avon Longitudinal Study of Parents and Children).121 I 
don’t know if you’re all familiar with that? It was an epidemiological study of 
14,000 mothers and 14,000 babies. To me, the initiation of a study of this scale 
raised a challenge to the question: ‘Can you just do it on a case-by-case basis?’ 
Clearly, when you’re asked to set up ethical principles for a study like this you 
have to do something overarching before you start looking at individual cases, 
and that’s in fact what our ethics committee did. 
What I think was unique at the time, although now it’s more common, was 
that our committee was asked to formulate the principles that would guide the 
study as a whole – then respond to them as things came along. In setting up 
the principles, we had to have some sort of common policy. On our committee 
of ten there was one philosopher, a theologian, and a couple of lawyers. Most 
of the others were doctors and scientists, so not a lot of people with a formal 
background in medical ethics or in moral philosophy. Nevertheless, we had to 
sit down and draw up principles, and use them in application in the study. It 
was at least in part a genetics-based study but a very different sort of thing from 
the clinical practice, or even from the sorts of clinical trials in which people 
here might have been involved, because of its size and scope, the nature of the 
questions we were asking and the samples that we were looking at.
Lucassen:  Can you say a little bit about the sorts of principles that you came 
up with?
Mumford:  On the first meeting, perhaps the first two meetings, we decided the 
essential issues to be addressed. These were confidentiality, consent, and the 
reporting of results to participants. Confidentiality, I think, was more or less taken 
as given at that point, at least as far as the genetic side of things was concerned.122 
The biological samples we were looking at were maternal and cord blood, and 
121  ALSPAC began in 1991 at the University of Bristol and is an ongoing study; www.bristol.
ac.uk/alspac/about/ (accessed 30 June 2015). The Study was also the subject of a Witness Seminar; 
Overy, Reynolds, and Tansey (eds) (2012). 
122  Mrs Elizabeth Mumford wrote, ‘There were issues that arose in terms of other parts of the study: 
questionnaires and face-to-face meetings, but as far as the biological samples were concerned, it seemed 
pretty clear.’ Note on draft transcript, 12 January 2015. 
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maternal urine. The genetic testing was done on the maternal and cord blood. It 
was clear to us that we owed a duty of confidentiality to the subjects. 
Consent was a more difficult issue because of the prevailing guidance at the time. 
In fact, when we were drawing up our principles, most of what would become 
prevailing guidance hadn’t yet been published. But the guidelines that came soon 
afterwards from the Royal College of Physicians, for example, said that if you 
were doing, as we did, and simply taking for research use an additional small 
amount from samples that were already being collected for clinical purposes, there 
was no need to seek either consent from the patient, or even ethics committee 
approval.123 Yet, at the same time, some of the advice that was coming out about 
genetics was that, if you were doing genetic testing, it was necessary to seek 
individual consent for every single test. You must seek individual consent, but 
possibly not if the sample was anonymized.124 In time we had to grapple with the 
apparent contradiction between these two points of view, but, of course, that was 
in the future. At this point we had no professional guidance. On the committee’s 
conclusions, it’s interesting, the chair was an academic lawyer, a very eminent 
academic lawyer, Professor Michael Furmston, and the very junior secretary was 
another academic lawyer – that was me.125 Never underestimate the power of the 
minutes’ secretary! [Laughs]. What you write up really matters. We took the view 
that, although we didn’t think we had a legal duty to seek consent, we felt there 
was an ethical obligation to do so, and so we did. This is the wording that we used 
in the letter that was sent to participants: ‘We will be keeping some of the blood 
and urine that is routinely taken during pregnancy. We will keep the placenta 
once the baby is born. With the blood we will be able to find out whether you 
have an allergy and whether your genes affect the health of your baby.’126 So we 
got the word ‘genes’ in, but it was surrounded by a lot of other material because 
we didn’t want to terrify people. We thought people were afraid of genetics, and 
if they saw the word they’d think, ‘Oh, they’re going to clone us!’ [laughter] or 
‘They’re going to find out that the paternity of the baby is something other than 
what we’d expected’. But we felt we had to say something about genetics, and 
there was a formal, written consent for the use of biological samples. 
123  Royal College of Physicians (1994). 
124  See, for example, Nuffield Council on Bioethics (1993).
125  Michael Furmston was Professor of Law at the University of Bristol from 1978 to 1998, now Emeritus. 
126  Quoted from the initial information that was sent to participants in 1990, entitled ‘Joining in Children 
of the Nineties: Questions and Answers’. Email from Mrs Elizabeth Mumford to Ms Emma Jones, 
11 November 2015. 
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Although those samples were collected during pregnancy, because that’s when 
it was routinely done, we felt that this was not an appropriate time to be asking 
people for consent to the study, because they were being asked for consent about 
things like alpha-fetoprotein, which they really needed to think about because it 
might have a bearing on their own lives. So the consent was actually done some 
considerable time after the samples had been collected. We told the participants 
that we would not be using the samples without their written consent. Again, 
the words we chose mattered very much afterwards: ‘… but we won’t do any 
of these tests unless you give us your permission’, which meant that we had all 
those samples stored and ready to use, but nothing could be done until much 
later when these people had been tracked down, and consent either given or 
refused. The other thing that I just found myself saying, which is worthy of 
noting, is that I’m saying ‘we’ all the way through my remarks. Although I was 
not doing the study myself, this gives you an idea of the way in which we all got 
very caught up in it, and we really felt we were part of the whole study.
Clarke:  I just want to say a couple of quick things: one was to go back to the 
loneliness thing. In addition to all the reasons why we feel the weight of what’s 
happening with the families, certainly for a phase of a good decade or more, 
a lot of people were very lonely in clinical genetics because they were running 
units on their own. They didn’t have ward rounds, and they didn’t have people 
coming in and out of the clinic room. You were driving off to a unit 100 miles 
away to do a clinic and then driving back again on your own, and you were on 
your own out there too, so there are lots of reasons for feeling lonely, I think. 
Coming back to the train of thought about feeling the weight of things for the 
families, and I think something that was very influential for me and I think for a 
whole generation of people coming through clinical genetics was the experience 
of getting involved in linkage studies during the 1980s. These meant going out 
into people’s homes, maybe hundreds of miles away, seeing half a dozen people 
in a day. It meant going off to a village and rounding up members of the family 
affected, unaffected parents, at risk, all these people, and spending a day with 
them and then going off and doing the same the next day, and the same the 
day after that. So you had a real education in family dynamics and the impact 
of major genetic disease on those who are both affected, at risk, parents of, etc., 
etc. I think that affected the way a lot of us still around look at things. Things 
happen differently now [laughter] because of the technology, but that was what 
happened at that time.
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Fryer:  Well, I’d echo exactly what Angus has just said about linkage studies and 
traipsing round the country. I think it’s extraordinarily valuable. Going back 
to the loneliness issue and Nick feeling untrained. I can’t say when I went to 
Liverpool that I was untrained because I’d worked with Peter for three years, 
but I recognize the feeling of impotence when you’re seeing a patient and you 
may be giving them bad news. Unlike when I was a paediatrician, and you’d 
possibly say, ‘Well, I’ll see you again in clinic in six weeks’ time’, and you were 
following them up, you just did not have the resources to do that as a clinical 
geneticist when you’re looking after a population of two and a bit million. One 
of the tenets of our specialty is providing information and support. I think it’s 
the support bit that is very difficult if you’re on your own without any other 
professionals, without any other doctors often, but certainly without any other 
professionals. The genetic counsellor had many different roles, but one of them, 
certainly when I went to Liverpool, as a virtually single-handed consultant, was 
in providing support; that kind of follow-up to families was a really critical part 
of the genetic counsellor role.
Lucassen:  I think that’s really interesting because there’s information and there’s 
support, and if the genetic counsellors were doing mainly the support then 
perhaps it’s not surprising they’ve been more wrapped up in the ethical issues if 
indeed that’s true. 
Hallowell:  Can I just say, to make you all feel better, I have, as a social scientist, 
interviewed many hundreds of people who have been to genetic clinics and 
they love you [laughter]. They all feel completely supported and it is absolutely 
always a very positive experience for people, and I do worry on that basis. I 
mean, a lot of the patients that I’ve seen are going mainly through cancer genetics 
clinics, have very long consultations compared to your average consultation in 
the hospital and I think that will not last forever and a day, and these issues are 
very complicated. I’d like to say I think you’ve all been doing ethics ever since 
the very beginning. Well, how I see ethics. I do wonder how this will be carried 
forward into the future because there just aren’t the resources to provide this 
kind of service. So I just thought I’d make you all feel better.
Clarke:  We don’t give you research access to our failures. [Laughter]
Lucassen:  That was a conversation stopper, Angus. 
Bale:  I just wanted to pick up on something that Nina said. I totally agree with 
everything I’ve heard, and I thoroughly enjoyed working with all the clinical 
geneticists, but I just have a sense of a ‘but’ that I wanted to bring into the 
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conversation. Partly through my experience when we established the Human 
Genetics Commission (HGC), which is on the agenda, and I’m conscious that 
you and several other members are still here, so I’m feeling a bit like Elizabeth 
(Mumford) in being the secretary to the HGC.127 There was a conscious decision 
taken early on to get a mixed membership, very much lay-driven. I think what 
was interesting about that, I looked at it from behind the scenes, it was actually 
quite quickly that two groups emerged and we saw it particularly when we 
tried to get a panel of patients together. One panel whom you might call the 
rare diseases community, who came with a very much worshipful feeling about 
genetics generally, and one from a disability rights background, who came at it 
with quite a different perspective. I think it was always very interesting to have 
this debate, and I’m sure Martin (Richards) will recall where there was quite a lot 
of tension about whether we should be dealing with issues around reproductive 
choice and all those sorts of issues. So I think there is a quite interesting angle 
on this one which has slightly gone away, whether it’s just gone away from my 
radar but it doesn’t seem there’s quite such a polarized debate about it.
Lucassen:  You mean the Human Genetics Commission has gone away?
Bale:  Well, that’s gone away, I know, but I mean without HGC, I don’t get views 
from members such as Bill Albert and other opponents of genetics constantly 
lobbying me anymore.128
Lucassen:  Can you say a bit more then about the Human Genetics Commission?
Harper:  And particularly say how did it come about given the reluctance of 
Department of Health (DoH), initially, to have anything to do with something 
like that?
Bale:  Well, we’ve talked about this and I’ve been fascinated by Peter’s attempt 
to try and get the history of medical genetics together.129 We haven’t really had a 
proper look in the DoH files. I suspect a lot of what happened before, probably 
in the mid-1990s, was all around the Royal Colleges and maybe around a 
127  The Human Genetics Commission ran from 1999 to 2012, and was the advisory board for the 
UK government on human genetics-related policy issues; see http://webarchive.nationalarchives.gov.
uk/20121102204634/ and http://hgc.gov.uk/client/content.asp?contentid=5 (accessed 30 June 2015). 
128  Dr Bill Albert was a member of the Human Genetics Commission from 1999 to 2005; http://webarchive.
nationalarchives.gov.uk/20060810161251/http://hgc.gov.uk/client/content.asp?contentid=661 (accessed 7 
October 2015). See also Albert (2007). 
129  See note 7. 
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little bit of work that might have, I think Peter thought it might have, been 
paediatrics. What really sparked the interest in genetics in the department and 
I was part of that, which is probably why I have a post, was two things. One 
was the hype about gene therapy, which we shouldn’t forget predated some 
of the work around the Human Genome Project.130 From the early 1990s 
there was a Gene Therapy Advisory Committee, which predated all the other 
genetics commissions, and it was interesting because, of course, it brought in 
a research ethics dimension to some of the debates around genetics and what 
we might be able to do.131 It was a very interesting committee when I first got 
involved in it, not as a DoH employee but as someone from outside in the 
Health and Safety Executive, in that it almost felt like it was making decisions 
about treating individual patients, something an ethics committee wouldn’t do 
now. Subsequent to that, and I think Peter and I were reminiscing the other 
day, there was a very important report, which I must go back and read, by the 
House of Commons’ science and technology Select Committee. It reported 
in the mid-1990s – I think the report was just called Human Genetics – and 
I’ve always been very impressed with that inquiry. I always keep meaning to 
go back and look at that report, look at who was behind it, who the experts 
were.132 What was intriguing about it was that the recommendations were 
made, a government response was published, and one or two of the responses 
annoyed the committee, or one or two members of the committee. They did 
something that is quite unusual and one of the things that you never want to 
happen, which is they actually brought out a supplementary report in effect 
criticizing the government response.133 That then led to the establishment of 
130  See, for example, French Anderson (1989). 
131  The Gene Therapy Advisory Committee was first convened in 1989, chaired by Sir Cecil Clothier QC; 
see Taylor and Lloyd (1995). 
132  House of Commons Select Committee on Science and Technology (1996). The members of the 
committee were Mr Spencer Batiste, Dr Jeremy Bray, Mrs Anne Campbell, Cheryl Gillian, Dr Lynne Jones, 
Mr Andrew Miller, Mr William Powell, Sir Giles Shaw, Sir Trevor Skeet, Sir Gerard Vaughan, Dr Alan 
Williams. Specialist advisers were Professor David Porteous, MRC Human Genetics Unit in Edinburgh, 
and Dr Bryan Sykes, Institute of Molecular Medicine in Oxford; see pages ii, xviii. For details of the 42 
witnesses who testified to the committee, see pages v–vii. 
133  For the Government’s first response, published in January 1996, see Department of Trade and 
Industry (1996a). For the second response, published in June 1996, see Department of Trade and 
Industry (1996b). A copy of the latter, which is not widely available, is held at the Parliamentary Archives, 
www.portcullis.parliament.uk/calmview/ (accessed 11 August 2015). For further commentary on these 
responses, see Select Committee on Science and Technology (2001). 
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two committees, if I recall correctly. One was called the Advisory Committee on 
Genetic Testing – with the acronym ACGT, the four bases of DNA. The other 
one was set up slightly later, in what was then the Department of Trade and 
Industry, called the Human Genetics Advisory Commission, which Baroness 
Onora O’Neill chaired.134 John Polkinghorne chaired ACGT, and I’m sure there 
are probably people here who were on ACGT.135 I was brought in as secretary and 
I attended the last meeting to wrap it all up. Then it was replaced by the HGC, 
which started, it’s becoming a very long-winded answer to Peter’s question but it 
started, because the new Labour administration had a desire to tackle a number 
of areas where they thought it had gone very badly on things like GM food, and 
to really engage with the public. 
One was on agriculture and biotechnology, the AEBC (Agriculture and 
Environment Biotechnology Commission), and that didn’t really have a very 
comfortable time. HGC, I think, had a slightly easier time because it was 
tackling issues that people could see the benefits to them, personally, of genetics. 
I think what was novel about the Commission as well was that it was an intent 
to be independent and to work very much in the public domain, and actually 
to go out and try and engage with the public, which, many of my colleagues 
used to say, ‘That’s a very brave experiment. Good luck on that one’. We had 
some mixed signals there, so I personally found it a very rewarding part of my 
career and I look back on it with very fond memories. So that’s the background 
to it, broadly.
Lucassen:  It also very deliberately went out and tackled some of the ethical 
issues that came up in genetics, didn’t it? 
Bale:  Yes, I think in a way ACGT was an interesting committee when I look back 
on their reports because they tried to put guidelines in place and codes of practice, 
and voluntary codes and so on, and they also went out and did site visits, which 
sounded a bit like CQC (Care Quality Commission) inspections from the people 
who reported back. You actually would go to a genetic service, and I don’t know 
134  For a debate in the House of Commons in which the foundation of the Human Genetics Advisory Commission 
and the Advisory Committee on Genetic Testing are discussed, see HC Deb 19 July 1996, vol. 281 cc1405–78; 
http://hansard.millbanksystems.com/commons/1996/jul/19/science-policy-and-human-genetics (accessed 1 
July 2015). The Commission ran from 1996 to 1999, when its functions were included in the Human Genetics 
Commission; see http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/ab/Archive/HGAC/index.htm 
(accessed 1 July 2015). The philosopher Baroness (Onora) O’Neill of Bengarve was Principal of Newnham 
College, Cambridge (1992–2006), and Chair of the Nuffield Foundation (1998–2010). 
135  See Professor Marcus Pembrey’s comments on pages 69–70. 
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if anyone experienced them, and talk to people and almost peer review the service 
they were providing. But it tackled some of the ethical issues, and the Human 
Genetics Commission looked at clinical genetics through a very different lens, I 
think, with a much more lay perspective and tried to engage the public. Some of 
the early work on genetic privacy, which I forget what it ended up being called, 
Whose Hands on your Genes? 136 No, that was the consultation, and then it was Inside 
Information, I think, was the report.137 They tried to lay down, and I still look 
back occasionally for guidance on some of the points because they did lay down a 
very useful, broader set of ethical principles. I remember when Mike (Parker) was 
chairing some work on the 100,000 Genomes Project going back and looking at 
the report and trying to see if those frameworks would work for where we were then 
because it was a clinical genetics approach, and now we’re looking at genomics.138 
Richards:  Perhaps I could just slightly broaden the context because there are 
some things we haven’t talked about at all. This is from my own personal 
perspective, but I became involved in working in genetic clinics in the mid/late 
1980s. Two things I’d point out about that era: one was that I remember being 
very surprised, I mean having spent most of my life trying to get money out of 
funders to do research, that the MRC (Medical Research Council) practically 
came and gave us money. They were very interested in funding work around 
genetics because they clearly saw it as being developed and, as it were, producing 
new issues, and quite specifically funding social science work in that area. The 
other thing that’s not been mentioned is the Nuffield Council because their very 
first report, if I get it right, was on genetic testing.139
Lucassen:  1993.
Richards:  Some of the next few were also on genetic issues and it seems to 
me they were important, and someone who travels through some of those 
debates in an important way is Onora O’Neill.140 I do think we have to think 
136  Human Genetics Commission (2000). 
137  Human Genetics Commission (2002).
138  The ‘100,000 Genomes Project’ intends to sequence the genomes of patients of the National Health 
Service with rare diseases, members of their families, and those with more common cancers by 2017; 
www.genomicsengland.co.uk/about-genomics-england/ (accessed 1 July 2015). 
139  Nuffield Council on Bioethics (1993). The Nuffield Council on Bioethics was established in 1991, 
and has addressed topics such as genetic screening, donor conception, and genetics and behaviour; 
see http://nuffieldbioethics.org/about/ (accessed 7 October 2015).
140  See, for example, O’Neill (2002), Manson and O’Neill (2007), and also note 133. 
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about what research was getting funded. The other thing, a little bit after 
that, of course Wellcome set up its panel specifically on, what was it called, 
ethical issues, yes, but much of that was actually supporting work in relation 
to genetics in one sense or another.141 So there was a whole generation of 
PhD students getting funded on those programmes themselves, the whole 
increase of social sciences people, who had an interest in ethical issues. Lots 
of it actually focused directly on genetics. I mean, that was the central issue in 
all of that, I think it’s fair to say. 
Harper:  I think HGC was certainly successful in getting not just the problems 
of genetics but some of the ethical issues out to communities that weren’t 
familiar with them. I recall in particular, I think you were on it, Mark (Bale), 
a visit to the National Forensics Police Centre in Birmingham where we were 
duly shown around, and I remember somebody on the visiting group, when 
they had been describing all sorts of wild projects on potential criminality and 
things, somebody asked, ‘Now, what about your ethics committee?’ And there 
was a sort of dazed silence at the idea of an ‘ethics committee?’ It wasn’t that 
they just didn’t have one, it never even crossed their minds that there might 
be any need for ethical review. Then, when we did manage to get down to the 
question of the ethical oversight, they said, ‘Yes, there are three people who are 
responsible for overseeing it’, and I can’t remember the official titles. It turned 
out all these three people, ‘they’ were actually just one person who was in charge 
of it all. Now I don’t know if that made any difference, because the whole thing 
was privatized shortly afterwards but they certainly had their eyes opened and 
that was due to HGC. I hope that’s somewhere in the minutes, Mark. 
Bale:  Yes. I think it’s a very interesting example, and I think it also showed in 
some ways the advantages of having Baroness Helena Kennedy chairing the 
committee because she saw DNA in a different way.142 I think you are absolutely 
right, there was one guy who was custodian and the kind of gamekeeper and 
poacher, but they did in the end set up a national oversight committee and the 
HGC was represented on it. I’ve lost track of where they got to but that did 
really seem to open our eyes, I do recall, in that meeting. 
Pembrey:  If I could go back a little bit to the Advisory Committee on Genetic 
Testing, because, with Peter, I think we were both on that committee, I was from 
1996 to 1999, or something like that. One of the things I was landed with was 
141  The Wellcome Trust’s Biomedical Ethics Research Programme started in 1997. 
142  Baroness Kennedy QC chaired the Human Genetics Commission from 2000 to 2007. 
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chairing a subgroup on over-the-counter testing and we actually published in 
September 1997.143 There were two things that came out of that; the first thing is 
that when people say that the ethical and other types of practical considerations 
were ‘follow-on’ to the science that races ahead and so forth. This was the exact 
opposite. It turned out that we’d got all these principles and everything else, 
we had a press conference, we had a leader in The Times.144 I was on the Today 
programme and everything else.145 It turned out there was only a single company 
offering cystic fibrosis testing, and they folded in about six months, and it was 
long before ‘23andMe’.146 Of course, the whole thing has been revisited with 
advances in genome sequencing.147 That’s the first thing. 
The other thing I remember, and it brought into sharp focus this thing that 
we’ve been discussing, about whether there’s anything special about genetics 
compared with other issues, was that Matthew Parris, The Times journalist, was 
on that committee, and when we were saying, ‘Well, we’ve got to be so careful 
when this information is handed over because it doesn’t have implications for 
just the person…’, he said to me, ‘What’s all the fuss about? People can go 
and buy a pregnancy test over the counter! You know, what could be more 
important than whether they are pregnant or not?’ Our answer, of course, was, 
‘Yes, people know what pregnancy is, and it will become evident very shortly 
if the test is correct or not,’ and so on. We then had to try and argue the point 
that genetic information, carrier testing, or presymptomatic testing in some 
situations, was different. 
143  Sub-committee on ‘Over the Counter Genetic Testing’; see Advisory Committee on Genetic Testing 
(1997). 
144  Hawkes (1997). 
145  Daily current affairs programme on BBC Radio 4. 
146  ‘23andMe’ is a private company selling DNA self-testing kits that use saliva samples; see 
www.23andme.com/en-gb/ (accessed 1 July 2015). 
147  Professor Marcus Pembrey wrote: ‘Genetic testing has been revisited by the inclusion of the NHS as well 
as commercial genetic testing in the discussion. I was mindful of the UK White Paper on genetics in the 
NHS, Department of Health (2003). This triggered several reports, including Making Babies: Reproductive 
decisions and genetic technologies, Human Genetics Commission (HGC) 2006; and the HGC and UK 
National Screening Committee joint report on Profiling the Newborn – a prospective gene technology?, 
Joint Working Group of the Human Genetics Commission and the UK National Screening Committee 
(2005). Then there were a huge number of publications on the ethical aspects (including what to do about 
“incidental findings”) as genome analysis techniques advanced. Google funded “23andMe” in May 2007.’ 
Note on draft transcript, 27 August 2015. 
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The other thing I want to raise is that I became the consultant adviser in genetics 
to the Chief Medical Officer in 1989,148 and so there was a question of trying 
to establish some general principles, ethical and otherwise, for Population Needs 
and Genetic Services; Ian Lister Cheese and I worked on this document with the 
help of a lot of others.149 We produced it, and in, let me get the piece of paper 
itself, it was sent out in 1993, a letter from the Chief Medical Officer and also 
from the Chief Nursing Officer, and it was distributed very, very widely. The 
booklet itself has no identification on it as to whether it was from the Department 
of Health or anything. The printing is HMSO (Her Majesty’s Stationery Office) 
but beyond that there is nothing as to where it’s come from, so as soon as it 
separates from the covering letter, and I said, ‘Surely this is a bit odd?’ and I 
think Ian said, ‘No, it was just an error.’ But part of me thinks that, like the 
advice when I first came to the consultant adviser post, the question of prenatal 
diagnosis and selective abortion was too hot to handle when I arrived. This was 
very definitely something they wanted to not have to make a decision one way or 
another about. I think the one thing that it brings back to me is that the selective 
abortion side of things is something that really drove the engagement of all the 
ethical issues and so on, more than anything else, during the 1980s and 1990s.150 
Farsides:  I agree with you. I can give an example of another interesting silence on 
that issue. I had a student who was a very senior midwife and she was interested 
in termination of pregnancy on the basis of fetal anomaly, in fact identified 
during scanning rather than during any other form of testing. But she did a 
survey of all the leaflets that were available for women in antenatal clinics and 
couldn’t find one that mentioned termination of pregnancy. So there was this 
absolute separation between the idea that we can now give you this information 
and any suggestion that this is where it might lead in terms of the choice that 
you would make on the basis of that. 
Hallowell:  Sort of related but unfortunately it doesn’t follow on very well: I was 
just sitting here thinking about what Martin said about the funding opportunities. 
It’s clear, as far as social science is concerned, and its contribution to this area, 
funding opportunities like, for example, the Wellcome Trust programme, which 
involved taking young social scientists, philosophers, lawyers away to Hinxton, 
feeding them with a lot of very nice food and giving them workshops for two 
148  Professor Sir Donald Acheson was Chief Medical Officer of England from 1984 to 1991. 
149  Department of Health (1993). 
150  Ciba Foundation (1985). 
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or three days. These happened, I think the beginning was in the mid-1990s, 
I certainly was involved as a member of faculty in 1999 and 2000. And actually 
nurturing a whole group of these young academics must have had a very big 
impact on the sort of research that has been carried out and also the way in 
which the research is fed back into the clinic. Therefore, there is actually a 
translational sort of circle going on here, so lots of people were doing research 
on lived, ethical issues and translating it. In my research I always tended to go 
back to the clinicians; that’s why I know a couple of you in the audience and 
actually talk about my findings and how maybe information could be delivered 
in a different way or how families could be approached and things like that. 
So I suspect what I’m actually trying to say, the research is obviously affecting 
clinical practice but fundamentally the funding opportunities for research is 
going to be affecting those sorts of things.
Parker:  I’ll say something about the Genethics Club, I guess.151 One of the 
things I just wanted to pick up on is these issues, three of them in particular are 
enduring. They can’t be resolved for all time because these are real people, real 
families, and real decisions, so they’re always going to be around in one form or 
another. Reproductive decision-making continues to be one of the main issues 
in about a third of the cases; genetic testing of children is an issue in about a 
third of the cases, and about half the cases are to do with sharing information 
in families, or not sharing information in families. It’s got to be more than 100 
per cent because sometimes there’s more than one issue. Reproductive issues are 
particularly difficult ones for people to talk about and find ways of articulating; 
for example, reservations that a health professional or genetic professional might 
have about prenatal testing for what they consider to be a minor condition. You 
know, how do you talk about that and think through that issue when there are 
all sorts of taboos and anxieties about even talking about those things?
One of things that struck me about my own experience in thinking about ethics 
in genetics is just how rapidly, I can date it almost quite precisely, how rapidly 
it kind of took over my life and has become an issue across the field in a sort of 
more visible way. I arrived in Oxford and met Anneke and we set up a monthly 
discussion group in the regional genetics service in Oxford where difficult 
cases were discussed. No funding or anything like that, and that’s happened 
every month since 1999, so that’s a long time; and that’s essentially become 
an important thing. Very quickly after that other people in other units heard 
151  See pages 4–5, see also Parker (2012). 
Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research
73
about that and asked me and you to go and do those, so I ended up doing 
one, I think we went to Cardiff, we went to Newcastle and had similar types of 
discussions. Then, Anneke, Angus, myself, and Tara Clancy in Manchester got 
some money from the Wellcome Trust for a one-day meeting, essentially to bring 
together people working in genetics across the UK to just talk about the kinds of 
ethical issues that were arising in their work because it was clear that people were 
struggling with these things individually but also that there were differences; 
the different units were struggling with things in different kinds of ways. And 
several of the people here now were at that first meeting. I remember it really 
well because I decided we’d go around the room and get people to introduce 
themselves and say why it is they thought ethics was important in genetics, and 
we had a whole agenda for the day, but we spent the whole day going around 
the table. People talked about cases, and we recorded the day. I’ve still got the 
transcript of that, and it was incredible because it was so rich and so interesting.152 
At the end, someone said, ‘There will be a lot of value in this, running this again.’
Lucassen:  Karen Temple, I seem to remember, said that.153
Parker:  It may have been Karen. And so we set up, and that was 2000, and 
since 2000 we’ve had one of those, three of those, a year and they have moved 
around the country, no funding again. They have been attended by more than 
800 people in total, about 400 completely separate individuals – some people 
come on a regular basis. We’ve had an attendance for between 30 to 40 people 
each time, and about 450 cases, I think, presented, formally presented, and, of 
course, that leads to other discussions. I mentioned the themes that come out 
most. There have been times, I remember, when several of us have said, ‘Do we 
really want to have three this year?’, and there are people who say they want to 
have this, they want this to happen. So it’s symptomatic, I think, of, certainly 
not something that’s actually been driven by us, I think, it was just something 
that has kind of taken over. 
152  The transcript of the recording of the first Genethics Club (later Forum) meeting has been deposited at 
the Wellcome Library, London, however public access to it is closed under the Data Protection Act. Details 
of associated material from the Genethics Club archive that is publicly accessible are on the Wellcome 
Library’s catalogue: Archives and Manuscripts, reference SA/GEC. Email from Ms Zoe Fullard, Wellcome 
Library, to Ms Emma Jones, 11 January 2016.  
153  Professor Karen Temple has been a consultant clinical geneticist since 1990, and was instrumental in the 
development of the Wessex Genetics Service. She is Director of the Academic Unit of Human Development 
and Health at the University of Southampton; see www.southampton.ac.uk/medicine/about/staff/ikt.page 
(accessed 28 July 2015). 
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Lucassen:  I think one of the things that is rather unique about the Genethics 
Forum is that as a medic I’m very much always driven to try and find ‘the 
answer’. What to do, what should I do here, which is echoing what a lot of 
you have said: ‘We were pragmatic, we just had to get on with it.’ But having 
people from other specialties and other disciplines there to just reflect on the 
issues is incredibly valuable, not only as a sounding board but also to be able to 
construct a different way of coming with a solution than we’ve had any training 
or experience of doing, I suppose. So that’s where the humanities and social 
science involvement in thinking about the ethical issues in genetics has been so 
very helpful.
Parker:  Yes, I think this is quite interesting. Marcus, earlier in the day you talked 
about the pre-meeting, and one of the things that it’s tempting to think is that 
the Genethics Club is something special and unique and there may be elements 
of that to it, but my guess is that actually there’s a whole lot of discussion of this 
type going on in various places around the country and it’s just a place where 
that happens in a more visible way. 
Pembrey:  At the risk of sticking my neck out a bit …
Lucassen:  That’s what we want.
Pembrey:  I think what one wanted to get from this discussion and the ethical 
discussion, the discussion of the issues anyway and so on, is I don’t know quite 
what it is but it’s a sort of moral robustness with respect to situations that just 
don’t fit any of the basic rules that you come across. So I suppose it’s the practice 
and experience of framing the problem and framing the issues and coming to 
a practical solution. One that springs to mind particularly we saw with the 
neurogeneticist Michael Baraitser and others in the clinic; a woman who had 
come with her brother who was 22, was very severely mentally retarded, and 
had a very unusual face, unrecognizable syndrome and so on. And there was 
a cousin who was said to have the same thing and the nature of the pedigree 
suggested that, if those two boys were the same, it was probably X-linked. We 
left it at that but she rang up a week later to say that unexpectedly she was 
pregnant and she would like to consider a question of whether she’s carrying a 
boy or not, and so forth. So I contacted the institution where her cousin was 
and they said, ‘Well, we would have to get consent from the guardians and 
so on.’ It turned out that the parents had died, the mother had died, and the 
guardian was the mother’s brother, or ex-husband or something, and he was a 
belligerent person who hadn’t seen this person for two years and then refused 
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for me to go and see him. I just wanted to take a photograph, or to see him at 
least. And so the hospital said I can’t go: those are the rules. I took [the clinical 
geneticist] Mike Patton along as moral support and said, ‘I don’t care what 
you say, I’m going.’ You know, there’s no harm to this person whatsoever and 
it will be vitally important to help us and the family. We went into the ward 
to see him; they were all terribly nervous about it. I said, ‘Do you want me to 
sign anything?’ They didn’t have anything for me to sign, but it was an example 
of where, perhaps if we hadn’t had all those discussions over a long time, one 
might have been kowtowed and bullied into, ‘Well, if those are the rules then 
I’m afraid we can’t help.’ That’s one example that springs to mind where a good 
training in discussing ethical issues helps one deal with such obstacles. 
Turnpenny:  I think the importance of our discussions, they serve a number of 
functions, but, most importantly, is this sense of solidarity with one another, 
the sense of comfort that if we come to a decision about a very difficult issue, 
we’ve shared it with people. We have more confidence in the ultimate decision 
we make, even if it’s exactly the same decision we would have made anyway. We 
have some reasonable grounds for going ahead with confidence, and all that is 
not only important just for the way we deal with patients themselves, but it’s 
always been important in terms of good clinical governance, simple as that. 
We’re all meant to practise good clinical governance, and it’s one of the key areas 
of clinical governance for us in our specialty. 
On top of all of that, an issue which we are in theory vulnerable to, though 
doesn’t happen too often, but it is actually a medico-legal kind of backup, it 
has a medico-legal function if we are going to either face official complaints 
from patients to our employing organizations, or indeed potentially be taken 
to court for a course of action that we’ve taken or the way we’ve dealt with 
patients. Clearly, if we’ve had those discussions in important forums like our 
departmental teams, the Genethics Club, or indeed other areas, then we can 
hand on heart say that we know the decision we reached was one that was a 
consensus.
Modell:  Yes. Following on from what you’ve been saying, and looking back 
at what’s come out at this meeting, and with particular reference to prenatal 
diagnoses and selective abortion, the experience of the people who were 
working on this early in the 1970s, I think across the board, was that this was 
something that was not universally accepted or approved by their peers.154 But 
154  See, for example, Harris (1974). 
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what’s happened is, of course, is that it has become progressively more accepted 
by society. And it is very important to formulate this in the terms that you are 
talking about. It’s terribly important in showing the support of society for the 
kind of service that we offer. 
Lucassen:  I wonder if we want to say a little bit more about that?
Modell:  The medical ethical contingent, let’s say.
Lucassen:  So the relationship between medical ethics and the law; people are 
hinting at it.
Modell:  And between the individual doctor and the individual patients, and 
society.
Hallowell:  I was just listening to what you were saying and I was thinking that, 
and we’ve touched upon it throughout the day, I wonder about the extent to 
which the ethical issues are now changing as genetics and genomics is now 
changing. So while we still have those issues around reproduction, those ethical 
issues, we are actually now moving towards a different set of ethical issues 
within genetics clinics and within the mainstreaming of genomics. I wonder 
how that’s changing? Mike handily said there were three issues, and I think 
that those latter ones that you mentioned, which were the family and children, 
weren’t they? Giving children an open future, and the reproductive issues. Now 
we’re getting much more of a focus on the family through things like: should 
we disclose information that we find in genomic tests? What impact will that 
have on the individuals themselves and on their family members when they 
are not expecting those kinds of things? I wonder whether, as you rightly say, 
on some of the issues around reproduction maybe we’ve kind of come to terms 
with them as a society and now we’re actually focusing on another set of issues, 
which are the issues around disclosure and incidental findings, and what we do 
with lots of different kinds of information that may emerge in the future.
Modell:  Yes, we’ve come to a bit of a conclusion about the prenatal diagnosis 
issue but now a process exists in society for examining the dilemmas and then 
reaching some kind of social conclusion and I think it’s a very good thing, long 
may it continue.
Harper:  I just wanted to say a word about the last, or the bottom point, on the 
programme.155 It was about the international aspects, and it is fair to say that 
medical genetics has always been very international, partly because it’s small, 
155  See Table 1, page 3. 
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and partly because it always has been internationally focused. Bodies like the 
HGC and the various reports and committees, etc., they haven’t just had an 
effect in this country, they have certainly had a lot of effect right across the 
whole of continental Europe and in countries like Australia and even on the 
other side of the Atlantic. Correspondingly, we’ve been influenced by some of 
the things from abroad. And so I think this has been a valuable effect. I’d just 
like to mention France where, in the course of doing my interviews, one of the 
people I interviewed was Jean-François Mattei, who was a clinical geneticist, 
head of the department in Marseille, and he was for a number of years Minister 
of Health in France.156 In the early 1990s he was responsible for a bioethics 
law being introduced.157 He also set up the French national ethics commission 
in 1983,158 and he was able also to get the sort of issues we’ve been talking 
about today across, in terms of getting them encoded, if not in law at least in 
legal principles.159 This has had a very valuable role. I don’t think I know of 
anybody in this country who has had such political involvement. Most of us 
aren’t particularly political in our inclination but that’s very far from the case 
in France and, indeed, Arnold Munnich was adviser to President Sarkozy.160 So 
the French have done a very good job even though it’s perhaps been in a rather 
Napoleonic, legalistic way [laughter]. And then in a way the other extreme 
influence, I think it’s been very important, has been the effects in Eastern 
Europe where, not surprisingly, given that for many years they were directed 
to do this and that in every aspect of their lives, and genetic counselling, such 
as it was, was exceptionally directive.161 I have vivid memories of one Eastern 
156  A transcript of the interview with Jean-François Mattei (d. 2014) is freely available to download from 
the Genetics and Medicine Historical Network’s website at https://genmedhist.eshg.org/fileadmin/content/
website-layout/interviewees-attachments/jean-francois-mattei-interview.pdf (accessed 11 January 2016).
157  Loi no 94-653 du 29 Juillet 1994 relative au respect du corps humain (1); available to download at 
www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000549619&categorieLien=id (accessed 
28 September 2015). 
158  Comité Consultatif National d’Ethique. 
159  For a discussion of the recent history of bioethics in France, see Berthiau (2013).
160  Professor Peter Harper also interviewed Arnold Munnich; a transcript is available on the Genetics and 
Medicine Historical Network with biographical details; https://genmedhist.eshg.org/fileadmin/content/
website-layout/interviewees-attachments/arnold-munnich-interview.pdf (accessed 11 January 2016). 
161  See Cohen et al. (1997) for a study comparing genetic counselling practices in East and West Germany, 
both of which practised directive counselling methods, although they were found to be more prevalent in 
East Germany. 
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European visitor describing how she would first get the husband in the room 
and say, ‘Well, if I were you I wouldn’t marry her.’ And then she’d get the wife 
in separately and say the same, well the other way around, anyway. I remember 
looking rather horrified, and she said, ‘Well, that’s the way things are done’, but 
things have changed and I think again people in Eastern European countries 
have looked over here. 
I’ve even been rather immodestly pleased by the fact that I think my Practical 
Genetic Counselling had a bit of an effect.162 They printed 100,000 copies in 
Russia but unfortunately they hadn’t signed the copyright law so I didn’t get 
anything out of it.163 [Laughter] But perhaps 30 years later, I had a Russian 
geneticist at a conference who came clutching the first edition, saying, ‘I use 
it every day.’164 [Laughter] And I remember looking rather alarmed and saying, 
‘Well, really you should get it up to date!’ [Laughter] … but he seemed quite 
happy with it. I gave him a copy of the current edition. 
So I do think there is a big international dimension to what we do both in 
practice and in terms of our wider discussions, and I think it’s worth also looking 
at that perspective of it. 
Hodgson:  That rang a bell because about two years ago I went to India to a 
cancer genetics conference and people kept rushing up to me and saying, ‘Can 
we have your rules, your protocols, your ethical advice?’ So that was rather good. 
Modell:  Yes, the international dimension isn’t limited to Europe at all. I was 
going to mention the example of Iran, which has a national policy about 
genetic counselling based on the ethical principles that were developed here, 
very explicitly, and using the methods which have been used in face-to-face 
counselling.165
Lucassen:  It’s six o’clock so I’m just going to call on people for rounding off 
comments now. 
Pembrey:  Well, in terms of the international thing, I just wanted to say that, 
probably, because I was Consultant Adviser to the Chief Medical Officer at 
the time, I was one of two people invited to the expert group of ‘Advisers on 
162  Harper (1981), first edition; latest edition revised by Professor Angus Clarke, see Clarke (2015). 
163  Harper (1984). 
164  Professor Peter Harper wrote, ‘He had travelled for three days by train from the Russian Far East to reach 
the meeting!’ Note on draft transcript, 1 December 2014. 
165  Iran’s clinical genetics services are discussed in, for example, Samavat and Modell (2004).
Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research
79
the Ethical Implications of Biotechnology’ for the European Commission in 
Brussels on prenatal diagnosis, and this was a two-year cycle and then produced 
a document and so on.166 And so, again, what we were developing in Britain had 
been fed into the European scene.
Dennis:  Well, could I just volunteer that my understanding of our discussion 
today is, between about 1980 and 2000 there was an influx of non-medical 
people into genetic counselling, which coincided with, and was probably the 
cause of, increasing explicitness about the ethical underpinnings of our practice. 
I think it’s been made clear that clinical genetics led the way within medicine in 
doing that. I hope that, and I believe that, in the same way as the development 
of genetic expertise could be diffused out into the rest of medicine, and indeed 
needed to be done so, and I think has been done; it sounds as if these ethical 
underpinnings are also being diffused out into the rest of medicine. I feel rather 
proud to be part of this specialty that seems, on the whole, to have done things 
rather well over the period of my career.
Turnpenny:  Just very quickly on the international side. Something that does 
interest me, and concerns me a little bit in coming back to the Beauchamp 
and Childress principles, is that the justice principle always seemed to me one 
that is under great stress the whole time because it’s all about equity of access 
to healthcare, and we know that is hugely problematic across the world, but it’s 
certainly a problem for genetics, the availability of genetic advice and testing 
expertise, certainly laboratory testing. It’s something that I think does, and 
should, exercise us in the ethical realm. I think it’s going to become increasingly 
difficult for us in the immediate future, and short and medium term, given 
the constraints that we are going through in the health service at the moment, 
where our availability to be involved in other ways outside our core work is 
coming under increasing pressure.
Parker:  I’m strongly of the view, and have written on this, that there is a sort of 
moral craft element to clinical genetics that is very important, and internal.167 I 
do also think it’s very important to emphasize, and we haven’t said much about 
the important role played by social science, and we’ve got Nina and Martin here 
166  ‘The group [of Advisers of the Ethical Implications of Biotechnology of the European Commission], 
which began work in 1991, is charged with finding ways to reconcile technological progress and ethical 
imperatives. “Its opinions help guide the European Community in its legislative and other activities”’; 
quoted from Group of Advisers on the Ethical Implications of Biotechnology (1996). 
167  For further discussion of ‘moral craft’, see Parker (2012), in particular pages 125–7, 129. 
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and others as well. The kind of findings, the evidence that they’ve found, and 
the analysis they’ve made of what’s happening in the clinic and ways in which 
families and the public think about these things and the whole experience of 
being involved in genetics, along with ethics, which has tended in this area to 
be a sort of empirical ethics. Bobbie and I both work in that sort of area. I think 
that’s helped. It’s partly internal and it’s partly about these other disciplines 
being drawn into a space as well. 
Richards:  A final reflection on that point. I’ve always assumed or thought what 
we do for a living in this field was social science, but I think at this point I 
realise that we’ve been doing ethics. I’m reflecting back to the issue you raised 
about what are ethics? What are principles? What are we talking about? We are 
talking about, I guess, a set of social relationships effectively, and it seems to me 
the social scientists were part of that, people like Mike, Bobbie, as well as the 
clinicians themselves. It’s been an interesting conversation over the last 30 to 
40 years. 
Lucassen:  Yes, and what struck me in the last few hours is our different 
understanding of, when we use the word ‘ethics’, quite what we mean by it, but 
I think it’s been a very rich conversation and I’ve certainly learnt a lot. I don’t 
know if anyone wants any last word but otherwise I suggest closing the meeting. 
Mike?
Parker:  I just think what you said is really important because I feel that the 
role that we’ve all played, and I don’t just mean the ethicists or social scientists, 
all of us, is to try to keep this conversation open and ongoing and alive. And 
that’s actually why important progress has been made in this area, but it’s a very 
creative area as well as being good for patients, hopefully, and their families. 
Lucassen:  That sounds like a very positive note … oh, Nick is going to follow 
that up.
Dennis:  When I said I was proud, I didn’t mean I was proud just of the medical 
bits, and I think one of the things I’m most proud of is the open mindedness of 
the medical people in clinical genetics inviting other disciplines in. I think that’s 
been very productive.
Tansey:  If I could just say thank you all very much for coming and contributing 
this afternoon. We will be back to all of you to ask for further elucidation and 
details to make this a very useful contribution to the history of the field. As I 
said at the beginning, nothing will be published without your permission; you 
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wouldn’t expect otherwise, would you? We are going to be ethical, [laughter] we 
will ask you for your copyright and if you wish to withhold any information you 
have every right to do that – but I hope you won’t. It’s been a fascinating afternoon 
and thank you all very much for bringing your very different contributions; I’m 
particularly delighted to thank you, Anneke, for your excellent chairing. 
Lucassen:  Thank you.

Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research – Biographical Notes 
83
Professor Richard Ashcroft 
MA(Cantab) PhD(Cantab) 
FHEA FRSB (b. 1969) studied 
mathematics before graduating 
in history and philosophy of 
science at Cambridge in 1990. 
He completed a PhD on ethics 
in science, again at Cambridge, 
under Professor John Forrester and 
Professor Nick Jardine in 1995. 
From 1995 to 1996 he was research 
fellow in the Department of 
Philosophy at Liverpool University, 
working on a study of ethics in 
clinical trials, funded by the NHS 
Health Technology Assessment 
programme and led by Professor 
Jane Hutton. He subsequently 
became Lecturer at the Centre for 
Ethics in Medicine under Professor 
Alastair Campbell (1997–2000) 
and Lecturer (and subsequently 
Senior Lecturer and Reader) in 
Biomedical Ethics at Imperial 
College London in the Department 
of Primary Care and General 
Practice (2000–2006). In 2006 he 
became Professor of Biomedical 
Ethics in the School of Medicine 
and Dentistry at Queen Mary 
University of London, moving to 
the School of Law in 2007.  He 
has been a member of the Gene 
Therapy Advisory Committee, 
the ethics committee of the Royal 
College of Obstetricians and 
Gynaecologists, and the Ethics of 
Research and Patient Involvement 
Committee at the Medical Research 
Council. He is currently a member 
of the Tobacco Advisory Group at 
the Royal College of Physicians of 
London, the ethics advisory board 
of Genomics England Ltd., and the 
working party on genome editing at 
the Nuffield Council on Bioethics. 
He was for several years Deputy 
Editor of the Journal of Medical 
Ethics. He works mainly on ethics 
in biomedical research and public 
health ethics.
Dr Mark Bale
PhD (b. 1962) studied applied 
biology at Cardiff, and was a 
researcher in microbial genetics 
at Bristol. He joined the UK 
Government’s Department of 
Health (DoH) in 1999 where he 
led on genetics and genomics from 
2004 and was Secretary to the 
Human Genetics Commission. 
He is Deputy Head of Health 
Science and Bioethics in the 
DoH, and leads on a number of 
key emerging healthcare science 
areas and their ethical, legal, and 
Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources.
84
Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research – Biographical Notes 
policy implications.  He is also 
Head of Profession for Scientists 
and Engineers, and a Deputy 
to the Chief Scientific Adviser, 
Professor Dame Sally Davies. He is 
currently working on the delivery 
of the Prime Minister’s 100,000 
Genomes Project, which includes 
the establishment of Genomics 
England to realise the project in 
close collaboration with NHS 
England and Health Education 
England. He also represents the 
UK on bioethics and biotechnology 
at the Council of Europe and 
the Organisation for Economic 
Cooperation and Development. He 
is Chair of the Council of Europe’s 
Committee on Bioethics. 
Professor Angus Clarke
DM FRCP FRCPCH (b. 1954) is 
Professor and Honorary Consultant 
in Clinical Genetics (Cardiff 
University and the Cardiff and 
Vale University Health Board). 
He graduated in genetics from 
Cambridge in 1976 and in 
clinical medicine from Oxford 
in 1979, and his pre-registration 
posts were at the John Radcliffe 
Hospital. He then trained in 
general medicine, paediatrics, and 
neonatal medicine before working 
on a research project on X-linked 
hypohidrotic ectodermal dysplasia 
with Professor Peter Harper. He 
moved to Newcastle and worked 
in both clinical genetics and 
paediatric neurology, establishing 
a genetic register for Duchenne 
muscular dystrophy and developing 
an interest in Rett syndrome. He 
returned to Cardiff in 1989 as 
Senior Lecturer in clinical genetics. 
Since then he has developed 
interests in newborn screening, 
genetic counselling, and in the 
social and ethical aspects of human 
genetics. He established, and 
directs, the Cardiff University MSc 
course in genetic counselling. 
Dr Nick Dennis
MB BChir (Cantab) FRCP 
(b. 1944) trained in clinical 
genetics with Professor Cedric 
Carter at the Institute of Child 
Health, London (1972–1976), 
then worked with Professor Robin 
Bannerman in Buffalo, New 
York State (1976–1978). He was 
appointed Senior Lecturer in 
Clinical Genetics at the University 
of Southampton and Honorary 
Consultant to the Southampton 
University Hospitals Trust in 1978. 
From then until his retirement 
in 2007, he helped to plan and 
provide a clinical genetics service 
to the Wessex Health Region as 
well as participating in research 
and teaching in the University 
of Southampton.
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Professor Bobbie Farsides 
PhD studied at the London School 
of Economics, where she completed 
her doctoral research in 1992. She 
was a lecturer in the Department 
of Philosophy at Keele University 
(1986–1996), and Director of its 
Centre for Contemporary Ethical 
Studies from 1992 to 1996. She 
moved to the Centre of Medical 
Law and Ethics at King’s College 
London as Lecturer/Senior in 
Medical Ethics (1996–1999;  
1999–2006). She was appointed 
Professor of Clinical and 
Biomedical Ethics at the Brighton 
and Sussex Medical School in 
2006, in which post she remains. 
She serves on many medical ethics-
related committees, including: 
the British Medical Association 
Ethics Committee (2006–); 
Institute of Medical Ethics (board 
member/trustee 2008–); Brighton 
and Sussex University Hospital 
Trust (BSUHT) Clinical Ethics 
Committee (2001–); BSUHT 
Organ Donation Committee 
(2008–); UK Donation Ethics 
Committee (2010–); Medical 
Research Council Brain Bank 
Network Steering Committee 
(2010–); Emerging Science and 
Bioethics Advisory Committee 
(2012–); and Human Fertilisation 
and Embryology Authority’s 
National Donation Strategy Group 
(2012–). Since 2013 she has been 
Chair of the Nuffield Council for 
Bioethics Working Party ‘Children 
and Medical Research: Finding a 
way forward’. She is also co-editor 
of the Royal Society of Medicine 
journal Clinical Ethics.
Dr John Fraser Roberts
CBE DSc FRCP FRCPsych FRS 
(1899–1987) began research in 
human genetics in Edinburgh 
during the 1930s. After the Second 
World War, he was Honorary 
Consultant in Medical Genetics 
at the Royal Eastern Counties 
Hospital, Colchester (1946–1957). 
He started a genetics clinic in 1946 
at the Hospital for Sick Children, 
Great Ormond Street, London, the 
first in Europe, and in 1957 the 
Medical Research Council created 
a Clinical Genetics Unit at the 
Institute of Child Health, Great 
Ormond Street, with Fraser Roberts 
as Director, where he remained 
until his retirement in 1964. He 
also started a genetics clinic at the 
Children’s Hospital, Bristol, in 
1957; see Pembrey (1987),  
Polani (1987), and Hill (1988). 
Dr Alan Fryer 
MD MRCP FRCP FRCPCH 
(b. 1954) trained at St Thomas’ 
Hospital Medical School, 
University of London, and was 
awarded a Membership of the 
Royal College of Physicians 
(Paediatrics) in 1974. His training 
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continued at St Thomas’ Hospital, 
where he was house physician, 
then house surgeon at Burton 
General Hospital, Stoke-on-Trent 
(1979), followed by casualty officer 
in Sheffield Children’s Hospital 
(1981), then Senior House Officer 
posts: neonatal paediatrics at Bristol 
Maternity Hospital (1981–1982); 
general paediatrics at the Royal 
Victoria Infirmary, Newcastle-
upon-Tyne (1982); community 
paediatrics, Gateshead (1982–
1983); and paediatric cardiology, 
Freeman Hospital, Newcastle-
upon-Tyne (1983). He was 
Paediatric Registrar at Southmead 
Hospital, Bristol (1983–1984), and 
then at the Royal United Hospital, 
Bath (1984–1985), where he was 
also a Research Fellow in the Bath 
Unit for Research into Paediatrics 
(1985–1987). He became 
Lecturer in Medical Genetics at 
the University of Wales College of 
Medicine, Cardiff, in 1987, until 
his appointment as Consultant 
Clinical Geneticist at the Royal 
Liverpool University Hospital; 
Royal Liverpool Children’s 
Hospital; Liverpool Women’s 
Hospital; and the Countess of 
Chester Hospital, in 1990, in 
which post he remains. He is also 
Honorary Lecturer at the University 
of Liverpool.  Since 2004 he has 
been an associate editor for Archives 
of Diseases in Childhood, and, since 
2009, he has been a peer reviewer 
for pre-implantation genetic 
diagnosis applications on behalf 
of the Human Fertilisation and 
Embryology Authority. 
Dr Nina Hallowell 
BSc (Hons) DPhil MA. (b. 1957) 
is an applied medical sociologist 
who also has an MA in medical 
ethics and law. She has worked 
at Newcastle University, the 
Universities of Cambridge and 
Edinburgh, and the Institute of 
Cancer Research in London. She 
was a Reader in Social Science and 
Public Health at the University of 
Edinburgh and now works as an 
independent research consultant  
in the UK and Australia. In the  
mid-1990s she moved to 
Cambridge to work with Martin 
Richards on an MRC-funded 
project that looked at families’ 
experiences of genetic testing for 
late-onset disorders, primarily breast 
and ovarian cancers. This project 
triggered a long-term interest in 
the impact of genetic testing on 
families, and she has researched this 
topic ever since. She has published 
over 60 articles in a range of 
medical, social science, and ethics 
journals. She has sat on a number of 
research ethics committees and is a 
member of the Ethics Group of the 
UK’s National DNA Database at 
the Home Office. 
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Professor Peter Harper
Kt FRCP (b. 1939) graduated 
from Oxford University in 1961, 
qualifying in medicine in 1964. 
After a series of clinical posts, he 
trained in medical genetics at the 
Liverpool Institute for Medical 
Genetics under Cyril Clarke and 
at Johns Hopkins University, 
Baltimore, under Victor McKusick. 
He was Professor of Medical 
Genetics at the University of Wales’ 
College of Medicine, Cardiff, from 
1971 until his retirement in 2004, 
when he was appointed University 
Research Professor in Genetics, 
Cardiff University (Emeritus since 
2008). He served on the UK’s 
Human Genetics Commission from 
2000 to 2004 and from 2004 to 
2010 with the Nuffield Council 
on Bioethics. He has been closely 
involved with the identification of 
the genes underlying Huntington’s 
disease and muscular dystrophies, 
and with their application to 
predictive genetic testing. He 
has also been responsible for the 
development of a general medical 
genetics service for Wales. His 
books include Practical Genetic 
Counselling (Harper, 1981); 
Landmarks in Medical Genetics 
(Harper (ed.), 2004); First Years 
of Human Chromosomes (Harper, 
2006), and A Short History of 
Medical Genetics (Harper, 2008). 
For the past decade he has led 
an initiative, supported by the 
Wellcome Trust, to preserve and 
document the history of human 
and medical genetics (https://
genmedhist.eshg.org/39.0.html). 
He is a consultant to the ‘Makers 
of Modern Biomedicine Project’ for 
the History of Modern Biomedicine 
Research Group, Queen Mary 
University of London.
Professor Shirley Hodgson
DM D(Obst) RCOG DCH FRCP 
(b. 1945), daughter of Lionel 
Penrose, avoided working in 
genetics for many years because of 
her father’s fame, but after training 
in medicine and working in general 
practice while her children were 
young, she did a locum in clinical 
genetics at Guy’s Hospital, and 
found the discipline irresistible. 
She went on to work in clinical 
genetics for many years. From 
1983 to 1988 she was Senior 
Registrar in Clinical Genetics for 
the South Thames (East) Regional 
Genetics Centre and Honorary 
Senior Registrar at Hammersmith 
Hospital, London, where she did 
her thesis in the study of Duchenne 
muscular dystrophy. She then 
moved to Addenbrooke’s Hospital, 
Cambridge (UK), as Consultant 
Clinical Geneticist (1988–1990), 
where she developed an interest 
in cancer genetics. She continued 
to promote this interest when 
she moved back to Guy’s and St 
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Thomas’ and also at St Mark’s 
Hospital in London in the 1990s, 
and ran the regional cancer genetics 
service for the South-East Thames 
Region. She has published widely 
on the subject of cancer genetics, 
and co-authored several books, 
including Inherited Susceptibility to 
Cancer (Foulkes and Hodgson (eds) 
(1998)) and A Practical Guide to 
Human Cancer Genetics (Hodgson 
and Maher (1993)), now into its 
fourth edition with W Foulkes and 
C Eng as co-authors (Springer). 
She is partially retired but did 
have an active research programme 
investigating inherited aspects of 
cancer predisposition, especially in 
breast and colorectal cancers. She 
took up a new post as Professor 
of Cancer Genetics at St George’s, 
University of London, in 2003, 
now Emeritus. She continues to 
do clinics in cancer genetics, in 
Leicester, and to teach in cancer 
genetics and global health. She 
has international interests, with 
teaching involvements in India  
and China, and is currently helping 
to develop the new medical school 
at the University of Namibia 
(UNAM).
Professor Anneke Lucassen 
MD PhD (b. 1962) studied 
medicine at the University of 
Newcastle-upon-Tyne and did her 
clinical training in Oxford, followed 
by a PhD in the molecular genetics 
of multifactorial disease at the 
Institute of Molecular Medicine 
(Oxford). She specialized in clinical 
genetics, with a particular interest 
in cancer and cardiac genetics. She 
was appointed as Consultant/Senior 
Lecturer in Oxford in 1997, then 
moved to Southampton in 2000 
and became Professor of Clinical 
Genetics in 2007. Over the past 
20 years she has applied her clinical 
and laboratory skills to focus on 
the ethical issues raised as new 
genetic technologies are integrated 
into the NHS, and she now leads 
an interdisciplinary programme of 
research into the social, ethical, and 
legal aspects of developments in 
genetics through the Clinical Ethics 
and Law unit at Southampton. In 
2001, supported by Wellcome Trust 
funding, she co-founded the UK 
Genethics Forum (previously Club), 
which has to date held 40 national 
one-day meetings to discuss ethical 
issues as they arise in clinical 
practice. She sat on the Nuffield 
Council of Bioethics from 2009 to 
2015, and on the Human Genetics 
Commission until 2012. She is 
a member of the Ethics Advisory 
Group for Genomics England. 
Professor Victor McKusick 
MD (1921–2008) qualified 
in medicine at Johns Hopkins 
University and completed his 
internship and residency in internal 
medicine there. He was Executive 
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Chief of the Cardiovascular Unit 
at Baltimore Marine Hospital 
(1948–1950), while progressing 
through the ranks in the Johns 
Hopkins Department of Medicine. 
He also held joint professorships in 
epidemiology in the Johns Hopkins 
University School of Public Health 
and in biology. He founded the 
Division of Medical Genetics in 
1957, which he headed until 1973, 
when he became the William 
Osler Professor and Chairman 
of the Department of Medicine, 
and Physician-in-Chief of Johns 
Hopkins Hospital. He held these 
posts until 1985, when he was 
named University Professor of 
Medical Genetics.
Professor Bernadette Modell
PhD FRCP FRCOG (b. 1935) 
undertook her first degree in 
zoology, predominantly in genetics 
and embryology, in Oxford 
in 1955; followed by doctoral 
research in developmental biology, 
Cambridge, 1959. She qualified 
in medicine at Cambridge and 
University College Hospital in 
1964, aiming to investigate the 
application of genetic knowledge in 
medical practice. She subsequently 
worked at University College 
London and University College 
London Hospitals until her 
retirement in 2000, where her 
work focused on thalassaemia as 
an example of a common genetic 
disorder. She was involved in 
developing effective treatment for 
thalassaemia major and prevention 
of the disease through community 
information; population screening 
and genetic counselling; and 
methods for prenatal diagnosis 
– including the first trimester 
diagnosis by chorionic villus 
sampling and DNA analysis. In 
collaboration with the WHO she 
has helped to extend programmes 
for the treatment and prevention 
of haemoglobin disorders to many 
parts of the world. She is currently 
Emeritus Professor of Community 
Genetics at the UCL (University 
College London) Centre for Health 
Informatics and Multiprofessional 
Education, where she works on the 
global epidemiology of congenital 
disorders, and developing 
informatics approaches to the 
provision of genetic information for 
communities. She is also Director 
of the WHO Collaborating 
Centre for Community Control 
of Hereditary Disorders. 
Mrs Elizabeth Mumford
LLM (b. 1958) was educated at 
Stanford University, the University 
of Toronto, and Queens’ College 
Cambridge. She was a lecturer 
in law at King’s College London 
and at Bristol University. She took 
an early ‘retirement’ in 2000 to 
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embark on a late career as a mother 
but still lectures on a part-time 
basis in medical law at Bristol.
Professor Michael Parker 
BEd MA PhD (b. 1958) is 
Professor of Bioethics and 
Director of the Ethox Centre at 
the University of Oxford. Before 
becoming an academic, he worked 
for more than a decade with 
homeless teenagers in London, 
mostly for a charity called 
Centrepoint Soho.  He did his 
undergraduate degree in education 
at Bristol Polytechnic (University 
of West of England) and a PhD in 
philosophy at Hull University. His 
first academic positions were at the 
University of Central Lancashire, 
the Open University, and Imperial 
College London. He moved to 
Oxford from Imperial College 
London in 1999. His overarching 
research interest is in the practical 
ethical aspects of the day-to-day 
work of health professionals 
and medical researchers, and 
the development of ‘moral 
craftsmanship’ in such contexts. 
He has a long-standing interest in 
the ethics of clinical genetics and, 
in 2001, together with Anneke 
Lucassen, Angus Clarke, and 
Tara Clancy, he established the 
Genethics Club – a national ethics 
forum for genetics professionals to 
identify and address ethical issues in 
their work. By 2015, the Genethics 
Club had met 40 times. This work 
is published as Ethical Problems 
and Genethics Practice (Parker 
(2012)). Michael’s other main 
research interest is in the ethical 
issues arising in collaborative global 
health research; again focusing 
on day-to-day practical ethics. 
Together with partners in Kenya, 
Thailand, Vietnam, Malawi, and 
South Africa, he co-ordinated the 
Global Health Bioethics Network, 
which is funded by a Wellcome 
Trust Strategic Award. 
Professor Marcus Pembrey 
MD FRCP FRCOG FRCPCH 
FMedSci (b. 1943) is Emeritus 
Professor of Paediatric Genetics 
at the Institute of Child Health, 
University College London and 
visiting Professor of Paediatric 
Genetics at the University of 
Bristol. He graduated from Guy’s 
Hospital in 1966 with an interest 
in paediatrics and medical genetics, 
then studied benign sickle cell in 
Eastern Saudi Arabia while training 
in clinical genetics with Paul Polani 
at Guy’s. In 1979 he was appointed 
head of the new Mothercare Unit of 
paediatric genetics at the Institute 
of Child Health and honorary 
consultant in clinical genetics at 
Great Ormond Street Hospital for 
Children. Here he helped develop 
clinical DNA analysis services, 
contributing to the Department 
of Health’s Special Medical 
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Development on this. His research 
focused on irregular inheritance, 
initially fragile X syndrome and 
then Angelman syndrome and 
genomic imprinting. This led to his 
current interest in transgenerational 
responses to early life exposures. 
He helped Jean Golding launch 
the Avon Longitudinal Study of 
Parents and Children (ALSPAC) in 
Bristol, being Director of Genetics 
within ALSPAC from 1989 to 
2005. He was Adviser in Genetics 
to the Chief Medical Officer UK 
(1989–1998) and President of 
the European Society of Human 
Genetics (1994–1995).
Professor Martin Richards 
PhD ScD (b. 1940) studied zoology 
at the University of Cambridge. 
He held a post-doctoral fellowship 
from the Science Research Council 
(1965–1967), and concurrently was 
research fellow at Trinity College, 
Cambridge (1965–1969). In 1966 
he was a visiting fellow at the 
Department of Biology, Princeton 
University, and then a visitor in 
the Center for Cognitive Studies at 
Harvard University (1967–1968). 
He founded the Family Research 
Group in Cambridge, in 1967,  
and became its Director until  
2005, when it was formally 
incorporated by the University.  
He held a series of academic posts 
at Cambridge University: Lecturer 
in Social Psychology (1970–1989); 
Reader in Human Development 
(1989–1997); Professor of Family 
Research (1997–2005); Head 
of Department of Social and 
Development Psychology (2005). 
Since 2005 he has been Emeritus 
Professor of Family Research at 
Cambridge. He was a member of 
the Human Genetics Commission 
(1999–2005), and the Ethics and 
Law Advisory Committee for  
the Human Fertilisation and 
Embryology Authority (2003–2009). 
Currently, he is a member of the 
Cambridge University Hospital 
NHS Foundation Trust’s Human 
Tissue Management Committee 
(2008–) and its Clinical Forum 
(2014–). 
Professor Tilli Tansey 
OBE PhD PhD DSc HonMD 
HonFRCP FMedSci (b. 1953) 
graduated in zoology from the 
University of Sheffield in 1974, 
and obtained her PhD in Octopus 
neurochemistry in 1978. She 
worked as a neuroscientist in the 
Stazione Zoologica Naples, the 
Marine Laboratory in Plymouth, 
the MRC Brain Metabolism Unit, 
Edinburgh, and was a Multiple 
Sclerosis Society Research Fellow 
at St Thomas’ Hospital, London 
(1983–1986). After a short 
sabbatical break at the Wellcome 
Institute for the History of 
Medicine (WIHM), she took a 
second PhD in medical history 
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on the career of Sir Henry Dale, 
and became a member of the 
academic staff of the WIHM, later 
the Wellcome Trust Centre for the 
History of Medicine at UCL. She 
became Professor of the History of 
Modern Medical Sciences at UCL 
in 2007 and moved to Queen Mary 
University of London (QMUL), 
with the same title, in 2010. With 
the late Sir Christopher Booth she 
created the History of Twentieth 
Century Medicine Group in the 
early 1990s, now the History of 
Modern Biomedicine Research 
Group at QMUL.
Professor Peter Douglas 
Turnpenny
FRCP FRCPCH FRCPath FHEA 
(b. 1953) is Consultant Clinical 
Geneticist at the Royal Devon 
and Exeter Healthcare NHS Trust 
and Honorary Associate Professor, 
University of Exeter Medical 
School. He graduated in medicine 
at Edinburgh University in 1977 
and initially pursued a career in 
paediatric medicine. Between 
1983 and 1990 he worked as a 
paediatrician (and anaesthetist) 
at The Nazareth Hospital, Israel 
(owned and governed by the 
Edinburgh Medical Missionary 
Society, now The Nazareth Trust). 
During the latter half of this period 
his interest in clinical genetics 
developed as he dealt with many 
paediatric medical conditions from 
a community with high levels of 
consanguinity. He returned to the 
UK in 1990 to a training position 
in clinical genetics in Aberdeen 
prior to moving to his consultant 
post in Exeter in 1993. As well 
as his interest in ethics related to 
medical genetics, he has clinical 
research interests in the genetics 
of spinal malformations, fetal 
anticonvulsant syndromes, and 
hypermobility. Since 2004 he has 
been the lead author of the award-
winning Emery’s Elements of Medical 
Genetics, whose 14th edition was 
published in 2011 (Turnpenny 
(2012)). From 2011 to 2013 he was 
President of the Clinical Genetics 
Society (UK). He has also been 
a Trustee of The Nazareth Trust 
since 2004 and helps Palestinians 
in their aspirations to develop 
genetic services. In April 2015 he 
was awarded an Honorary Clinical 
Professorship by the University of 
Exeter Medical School. 
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